

Comparative efficacy and safety of current therapies for early rheumatoid arthritis: a systematic literature review and network meta-analysis

D. Paul, M.S. Fazeli, L. Mintzer, L. Duarte, K. Gupta, L. Ferri

APPENDIX

Figure 1 Network Diagram for Withdrawal Due to Adverse Event




Figure 2 Risk of Bias for Analyzed Studies




Table 1 Search Results: MEDLINE® (via Pubmed/Ovid)

SET #	Searches (conducted 18 June 2018)	Results
1	"Arthritis, Rheumatoid"[Mesh]	105426
2	rheumatoid arthritis[tiab] OR RA[ti]	97628
3	1 OR 2	137537
4	"Antirheumatic Agents"[Mesh]	99515
5	"Antirheumatic Agents" [Pharmacological Action]	398403
6	"Adrenal Cortex Hormones"[Mesh]	270010
7	"Adrenal Cortex Hormones" [Pharmacological Action]	204875
8	Corticosteroid*[tiab] OR Cortico-steroid*[tiab] OR Corticoid*[tiab] OR Corti-coid*[tiab] OR Glucocorticoid*[tiab]	156831
9	Methylprednisolone[tiab] OR Medrol[tiab] OR Metipred[tiab] OR Urbason[tiab]	14934
10	Prednisolone[tiab] OR Predate[tiab] OR Predonine[tiab] OR DiAdresonF[tiab] OR Di-Adreson-F[tiab]	26867
11	Prednisone[tiab] OR Cutason[tiab] OR Dacortin[tiab] OR Deltasone[tiab] OR Dehydrocortisone[tiab] OR Orasone[tiab] OR Panasol[tiab] OR Prednison[tiab] OR Pronisone[tiab] OR Rectodelt[tiab] OR Sterapred[tiab]	26973
12	Adalimumab*[tiab] OR Adalimumab-atto[tiab] OR Humira[tiab] OR D2E7[tiab]	5529
13	Certolizumab pegol[tiab] OR Cimzia[tiab] OR CDP870[tiab] OR CDP 870[tiab]	617
14	Etanercept*[tiab] OR Enbrel[tiab] OR TNR-001[tiab] OR TNR001[tiab] OR TNTR-Fc[tiab]	6187
15	Etanercept-szsz[tiab] OR Erelzi[tiab] OR GP2015[tiab]	14
16	"golimumab" [Supplementary Concept] OR Golimumab[tiab] OR Simponi[tiab]	900
17	Infliximab*[tiab] OR Infliximab-adba[tiab] OR Infliximab-dyyb[tiab] OR MAB cA2[tiab] OR Monoclonal Antibody cA2[tiab] OR Remicade[tiab]	10705
18	Abatacept[tiab] OR Orencia[tiab] OR Belatacept[tiab] OR BMS188667[tiab] OR BMS-188667[tiab] OR BMS224818[tiab] OR BMS-224818[tiab] OR Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin[tiab] OR CTLA-4-Ig[tiab] OR CTLA4-Ig[tiab] OR CTLA4-Fc[tiab] OR LEA29Y[tiab] OR Nulojix[tiab]	2209
19	Rituximab[tiab] OR IDEC-C2B8[tiab] OR GP2013[tiab] OR Mabthera[tiab] OR Rituxan[tiab]	17360
20	"sarilumab"[Supplementary Concept] OR Sarilumab[tiab] OR Kevzara[tiab] OR REGN-88[tiab] OR REGN88[tiab] OR SAR-153191[tiab] OR SAR153191[tiab]	51
21	"tocilizumab"[Supplementary Concept] OR Tocilizumab[tiab] OR Actemra[tiab] OR atlizumab[tiab] OR RoActemra[tiab] OR MRA monoclonal antibody[tiab]	2306
22	Cyclophosphamide[tiab] OR B-518[tiab] OR B518[tiab] OR Cytophosphane[tiab] OR Cytophosphan[tiab] OR Cytoxan[tiab] OR Endoxan[tiab] OR Neosar[tiab] OR NSC-26271[tiab] OR NSC26271[tiab] OR Procytox[tiab] OR Sendoxan[tiab]	46323
23	Gold[tiab] OR Aurolate[tiab] OR Aurothiomalate[tiab] OR Monogold[tiab] OR Myochrysine[tiab] OR Miocrin[tiab] OR Myocrisin[tiab] OR Miocrisin[tiab] OR Myocrysine[tiab] OR Sodium Thiomalatoaurate[tiab] OR Tauredon[tiab]	133058
24	Hydroxychloroquine[tiab] OR Hydroxychlorochin[tiab] OR Oxychlorochin[tiab] OR Oxychloroquine[tiab] OR Plaquenil[tiab]	3327
25	Leflunomide[tiab] OR Arava[tiab] OR HWA 486[tiab] OR HWA-486[tiab] OR SU101[tiab]	2016
26	Methotrexate[tiab] OR Amethopterin[tiab] OR Mexate[tiab] OR MTX[tiab] OR Rheumatrex[tiab] OR Trexall[tiab]	39956
27	Sulfasalazine[tiab] OR Asulfidine[tiab] OR Azulfadine[tiab] OR Azulfidine[tiab] OR Colo-Pleon[tiab] OR Pleon[tiab] OR Salazopyrin[tiab] OR Salazosulfapyridine[tiab] OR Salicylazosulfapyridine[tiab] OR Ucline[tiab] OR Ulcol[tiab]	3576
28	"Interleukin 1 Receptor Antagonist Protein"[Mesh] OR Anakinra[tiab] OR Antril[tiab] OR Kineret[tiab]	5346

SET #	Searches (conducted 18 June 2018)	Results
29	"baricitinib"[Supplementary Concept] OR Baricitinib[tiab] OR INCB028050[tiab] OR LY3009104[tiab]	100
30	"tofacitinib"[Supplementary Concept] OR Tofacitinib[tiab] OR CP690550[tiab] OR CP-690550[tiab] OR CP-690,550[tiab] OR tasocitinib[tiab]	826
31	Azathioprine[tiab] OR Azothioprine[tiab] OR Imurel[tiab] OR Imuran[tiab] OR Immuran[tiab]	14681
32	Cyclosporine[tiab] OR Ciclosporin[tiab] OR Cyclosporin[tiab] OR CsA-Neoral[tiab] OR CsANeoral[tiab] OR CyA-NOF[tiab] OR Neoral[tiab] OR OL 27-400[tiab] OR OL 27400[tiab] OR Sandimmun[tiab] OR Sandimmune[tiab]	48995
33	"Penicillamine"[Mesh] OR D-penicillamine[tiab] OR beta,beta-Dimethylcysteine[tiab] OR Copper Penicillamate[tiab] OR Cuprenil[tiab] OR Cuprimine[tiab] OR Dimethylcysteine[tiab] OR D-3-Mercaptovaline[tiab] OR Metalcaptase[tiab]	8771
34	"Minocycline"[Mesh] OR Minocycline[tiab] OR Akamin[tiab] OR Aknemin[tiab] OR Akne-Puren[tiab] OR Aknin-Mino[tiab] OR Aknosan[tiab] OR Apo-Minocycline[tiab] OR Arestin[tiab] OR Blemix[tiab] OR Cyclomin[tiab] OR Cyclops[tiab] OR Dentomycin[tiab] OR Dynacin[tiab] OR Icht-Oral[tiab] OR Klinomycin[tiab] OR Lederderm[tiab] OR Mestacine[tiab] OR Minakne[tiab] OR Mino-Wolff[tiab] OR Minocin[tiab] OR Minoclr[tiab] OR Minolis[tiab] OR Minomycin[tiab] OR Minoplus[tiab] OR Minotab[tiab]	8666
35	OR/4-34	1034431
36	3 AND 35	40352
37	disease duration[tiab] OR early[tiab] OR earlier[tiab] OR earliest[tiab] OR first-line[tiab] OR firstline[tiab] OR 1st line[tiab] OR first presenting[tiab] OR first presentation[tiab] OR frontline[tiab] OR front-line[tiab] OR initial diagnosis[tiab] OR initial* treat*[tiab] OR initial therapy[tiab] OR initial therapies[tiab] OR naive[tiab] OR naïve[tiab] OR new diagnosis[tiab] OR new diagnoses[tiab] OR newly diagnosed[tiab] OR newly presenting[tiab] OR primary treatment[tiab] OR primary therapy[tiab] OR primary therapies[tiab] OR recent diagnosis[tiab] OR recent diagnoses[tiab] OR recently diagnosed[tiab] OR untreat*[tiab] OR un-treat*[tiab]	1012007
38	"Time Factors"[Mesh]	1123394
39	"Early Diagnosis"[Mesh:NoExp]	22635
40	"Severity of Illness Index"[Mesh]	222756
41	OR/37-40	2250748
42	36 AND 42	9546
43	"animals"[mesh] NOT "humans"[mesh]	4464552
44	42 NOT 43	9278
45	English[Language]	23911774
46	44 AND 45	8259
47	"1980/01/01"[PDAT] : "3000/12/31"[PDAT]	22853578
48	46 AND 47	7942

Table 2 Search Results: Embase (via Ovid)

Set #	Searches (conducted 18 June 2018)	Results
1	rheumatoid arthritis/	188331
2	rheumatoid arthritis.ti,ab.	13939
3	RA.ti.	6607
4	OR/1-3	208335
5	antirheumatic agent/	551331
6	exp tumor necrosis factor inhibitor/	73676
7	exp corticosteroid/	886488
8	(Corticosteroid\$ or Cortico-steroid\$ or Corticoid\$ or Corti-coid\$ or Glucocorticoid\$).ti,ab.	216354
9	(Methylprednisolone or Medrol or Metipred or Urbason).ti,ab.	22446
10	(Prednisolone or Predate or Predonine or DiAdresonF or Di-Adreson-F).ti,ab.	36106
11	(Prednisone or Cutason or Dacortin or Deltasone or Dehydrocortisone or Orasone or Panasol or Prednison or Pronisone or Rectodelt or Sterapred).ti,ab.	41830
12	(Adalimumab\$ or Adalimumab-atto or Humira or D2E7).ti,ab	14238
13	(Certolizumab pegol or Cimzia or CDP870 or CDP 870).ti,ab.	1633
14	(Etanercept or Enbrel or TNR-001 or TNR001 or TNTR-Fc).ti,ab.	12453
15	(etanercept-szss or Erelzi or GP2015).ti,ab.	21
16	(Golimumab or Simponi).ti,ab.	2133
17	(Infliximab\$ or Infliximab-adba or Infliximab-dyyb or MAB cA2 or Monoclonal Antibody cA2 or Remicade).ti,ab.	21983
18	(Abatacept or Orencia or Belatacept or BMS188667 or BMS-188667 or BMS224818 or BMS-224818 or Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin or CTLA-4-Ig or CTLA4-Ig or CTLA4-Fc or LEA29Y or Nulojix).ti,ab.	5216
19	exp rituximab/	65726
20	(Rituximab or IDEC-C2B8 or GP2013 or Mabthera or Rituxan).ti,ab.	36900
21	(Sarilumab or Kevzara or REGN-88 or REGN88 or SAR-153191 or SAR153191).ti,ab.	174
22	(Tocilizumab or Actemra or atlizumab or RoActemra or MRA monoclonal antibody).ti,ab.	5170
23	(Cyclophosphamide or B-518 or B518 or Cytophosphane or Cytophosphan or Cytoxan or Endoxan or Neosar or NSC-26271 or NSC26271 or Procytox or Sendoxan).ti,ab.	68361
24	(Gold or Aurolate or Aurothiomalate or Monogold or Myochrysine or Miocrin or Myocrisin or Miocrisin or Myocrysine or Sodium Thiomalatoaurate or Tauredon).ti,ab.	166799
25	(Hydroxychloroquine or Hydroxychlorochin or Oxychlorochin or Oxychloroquine or Plaquenil).ti,ab.	6167
26	(Leflunomide or Arava or HWA 486 or HWA-486 or SU101).ti,ab.	3632
27	exp methotrexate/	164478
28	(Methotrexate or Amethopterin or Mexate or MTX or Rheumatrex or Trexall).ti,ab.	64204
29	exp salazosulfapyridine/	23474
30	(Sulfasalazine or Asulfidine or Azulfadine or Azulfidine or Colo-Pleon or Pleon or Salazopyrin or Salazosulfapyridine or Salicylazosulfapyridine or Ucline or Ulcol).ti,ab.	5522
31	(Anakinra or Antril or Kineret).ti,ab.	2721
32	(Baricitinib or INCB028050 or LY3009104).ti,ab.	291
33	(Tofacitinib or CP690550 or CP-690550 or CP-690,550 or tasocitinib or tasocitinib).ti,ab.	1692
34	(Azathioprine or Azothioprine or Imurel or Imuran or Immuran).ti,ab.	23984
35	exp cyclosporin/	76067
36	(Cyclosporine or Ciclosporin or Cyclosporin or CsA-Neoral or CsANeoral or CyA-NOF or Neoral or OL 27-400 or OL 27400 or Sandimmun or Sandimmune).ti,ab.	66432

Set #	Searches (conducted 18 June 2018)	Results
37	(Penicillamine or D-penicillamine or beta,beta-Dimethylcysteine or Copper Penicillamate or Cuprenil or Cuprimine or Dimethylcysteine or D-3-Mercaptovaline or Metalcaptase).ti,ab.	8285
38	exp minocycline/	21966
39	(Minocycline or Akamin or Aknemin or Akne-Puren or Aknin-Mino or Aknosan or Apo-Minocycline or Arestin or Blemix or Cyclomin or Cyclops or Dentomycin or Dynacin or Icht-Oral or Klinomycin or Lederderm or Mestacine or Minakne or Mino-Wolff or Minocin or Minoclor or Minolis or Minomycin or Minoplus or Minotab).ti,ab.	8788
40	OR/5-39	1716086
41	4 AND 40	82942
42	exp time factor/	19452
43	exp early diagnosis/	94366
44	exp "severity of illness index"/	12023
45	(early or earlier or earliest or first-line or firstline or frontline or front-line or naive or untreat\$ or un-treat\$).ti,ab.	2470254
46	(disease adj3 duration).ti,ab.	58094
47	(first adj1 present\$).ti,ab.	11798
48	(initial\$ adj2 diagnos#s).ti,ab.	29173
49	(initial\$ adj2 therap\$).ti,ab.	20902
50	(initial\$ adj2 treat\$).ti,ab.	54991
51	(new\$ adj1 diagnos#s).ti,ab.	7297
52	(new\$ adj1 present\$).ti,ab.	8930
53	(primar\$ adj3 treat\$).ti,ab.	83066
54	(primar\$ adj3 therap\$).ti,ab.	26366
55	(recent\$ adj2 diagnos#s).ti,ab.	3927
56	OR/42-55	2749956
57	41 AND 56	18273
58	(exp animal/ or nonhuman/) not exp human/	6310208
59	57 NOT 58	17988
60	English.lg.	27434647
61	59 AND 60	16850
62	Case report.ti.	263363
63	61 NOT 62	16715
64	(article or article in press or conference paper).pt.	22847686
65	63 AND 64	6523
66	limit 65 to yr="1980 -Current"	6425
67	acr.cf.	19920
68	eular.cf.	19929
69	67 OR 68	39849
70	63 AND 69	4349
71	conference abstract.pt.	3038262
72	70 AND 71	4345
73	limit 72 to yr="2016 -Current"	1402
74	66 OR 73	7827

Table 3 Search Results: Cochrane Library (CENTRAL) (via Wiley).

Set #	Searches (conducted 18 June 2018)	Results
1	MeSH descriptor: [Arthritis, Rheumatoid] explode all trees	5752
2	rheumatoid arthritis:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	9090
3	RA:ti Publication Year from 1980 to 2018 (Word variations have been searched)	732
4	^{7-#3} Publication Year from 1980 to 2018	9951
5	MeSH descriptor: [Antirheumatic Agents] explode all trees	10022
6	MeSH descriptor: [Adrenal Cortex Hormones] explode all trees	13994
7	(Corticosteroid* or Cortico-steroid* or Corticoid* or Corti-coid* or Glucocorticoid*):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	16181
8	(Methylprednisolone or Medrol or Metipred or Urbason):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	2478
9	(Prednisolone or Predate or Predonine or DiAdresonF or Di-Adreson-F):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	3542
10	(Prednisone or Cutason or Dacortin or Deltasone or Dehydrocortisone or Orasone or Panasol or Prednison or Pronisone or Rectodelt or Sterapred):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	5257
11	(Adalimumab* or Adalimumab-atto or Humira or D2E7):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	1649
12	(Certolizumab pegol or Cimzia or CDP870 or CDP 870):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	307
13	(Etanercept* or Enbrel or TNR-001 or TNR001 or TNTR-Fc):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	1301
14	(Etanercept-szsz or Erelzi or GP2015):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	11
15	(Golimumab or Simponi):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	407
16	(Infliximab* or Infliximab-adba or Infliximab-dyyb or MAB cA2 or Monoclonal Antibody cA2 or Remicade):ab,ti Publication Year from 1980 to 2018	1480
17	(Abatacept or Orencia or Belatacept or BMS188667 or BMS-188667 or BMS224818 or BMS-224818 or Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin or CTLA-4-Ig or CTLA4-Ig or CTLA4-Fc or LEA29Y or Nulojix):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	601
18	(Rituximab or IDEC-C2B8 or GP2013 or Mabthera or Rituxan):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	2992
19	(Sarilumab or Kevzara or REGN-88 or REGN88 or SAR-153191 or SAR153191):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	98
20	(Tocilizumab or Actemra or atlizumab or RoActemra or MRA monoclonal antibody):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	570
21	(Cyclophosphamide or B-518 or B518 or Cytophosphane or Cytophosphan or Cytoxan or Endoxan or Neosar or NSC-26271 or NSC26271 or Procytox or Sendoxan):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	7410
22	(Gold or Aurolate or Aurothiomalate or Monogold or Myochrysine or Miocrin or Myocrisin or Miocrisin or Myocrysine or Sodium Thiomalatoaurate or Tauredon):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	5849
23	(Hydroxychloroquine or Hydroxychlorochin or Oxychlorochin or Oxychloroquine or Plaquenil):ab,ti Publication Year from 1980 to 2018	479
24	(Leflunomide or Arava or HWA 486 or HWA-486 or SU101):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	295
25	(Methotrexate or Amethopterin or Mexate or MTX or Rheumatrex or Trexall):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	6963
26	(Sulfasalazine or Asulfidine or Azulfidine or Colo-Pleon or Pleon or Salazopyrin or Salazosulfapyridine or Salicylazosulfapyridine or Ucline or Ulcol):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	567
27	MeSH descriptor: [Interleukin 1 Receptor Antagonist Protein] explode all trees	254
28	(Anakinra or Antril or Kineret):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	156
29	(Baricitinib or INCB028050 or LY3009104):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	161
30	(Tofacitinib or CP690550 or CP-690550 or CP-690,550 or tasocitinib):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	399
31	(Azathioprine or Azothioprine or Imurel or Imuran or Immuran):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	1759
32	(Cyclosporine or Ciclosporin or Cyclosporin or CsA-Neoral or CsA-Neoral or CyA-NOF or Neoral or OL 27-400 or OL 27400 or Sandimmun or Sandimmune):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	5366
33	MeSH descriptor: [Penicillamine] explode all trees	176

Set #	Searches (conducted 18 June 2018)	Results
34	(Penicillamine or D-penicillamine or beta,beta-Dimethylcysteine or Copper Penicillamate or Cuprenil or Cuprimine or Dimethylcysteine or D-3-Mercaptovaline or Metalcaptase):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	222
35	MeSH descriptor: [Minocycline] explode all trees	467
36	(Minocycline or Akamin or Aknemin or Akne-Puren or Aknin-Mino or Aknosan or Apo-Minocycline or Arestin or Blemix or Cyclomin or Cyclops or Dentomycin or Dynacin or Icht-Oral or Klinomycin or Lederderm or Mestacine or Minakne or Mino-Wolff or Minocin or Minocilr or Minolis or Minomycin or Minoplus or Minotab):ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	680
37	^{45-#36} Publication Year from 1980 to 2018 (Word variations have been searched)	65690
38	#4 and #37 Publication Year from 1980 to 2018 (Word variations have been searched)	5556
39	MeSH descriptor: [Time Factors] explode all trees	62703
40	MeSH descriptor: [Early Diagnosis] this term only	623
41	MeSH descriptor: [Severity of Illness Index] explode all trees	19147
42	(early or earlier or earliest or first-line or firstline or frontline or front-line or naive or untreat* or un-treat*):ti,ab Publication Year from 1980 to 2018 (Word variations have been searched)	125767
43	disease near/3 duration:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	3338
44	first near/2 present*:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	626
45	initial* near/2 diagnos?:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	640
46	initial* near/2 diagnosed:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	136
47	initial* near/2 therap*:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	2321
48	initial* near/2 treat*:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	5228
49	new* near/2 diagnos?:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	458
50	new* near/2 diagnosed:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	7920
51	new* near/2 present*:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	456
52	primar* near/3 treat*:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	10883
53	primar* near/3 therap*:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	3820
54	recent* near/2 diagnos?:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	143
55	recent* near/2 diagnosed:ab,ti Publication Year from 1980 to 2018 (Word variations have been searched)	545
56	^{39-#55} Publication Year from 1980 to 2018 (Word variations have been searched)	209887
57	#38 and #56 Publication Year from 1980 to 2018 (Word variations have been searched)	2429
58	#57 not (embase or MEDLINE® or pubmed) Publication Year from 1980 to 2018 (Word variations have been searched)	97

Table 4 Baseline Characteristics of Studies included in NMA

Trial Author Year	Abbreviated Name	Group N	Age, yr	Duration of RA	Gender, Female (%)	Race, Caucasian (%)	RF Positive n (%)	Anti-CCP Antibody Positive n (%)	DAS28	Total Sharp Score Modified Van der Heijde	Total Sharp Score Genant Modified
AMPLE	ABA+MTX	71	50	0.3 yr	83.1	84.6	NR	NR	5.5	NR	NR
Schiff M. (2014) ³⁴	ADA+MTX	70	52	0.3 yr	72.9	81.4	NR	NR	5.7	NR	NR
AVERT	ABA+MTX	119	46.4 ± 13.2	0.58 yr ± 0.5	79.83	84.03	95	NR	5.5 ± 1.3	NR	NR
Unknown (2010) ⁴⁰	ABA	116	45.4 ± 11.92	0.59 yr ± 0.522	76.72	81.9	95.7	NR	5.5 ± 1.1	NR	NR
Emery P (2015) ²⁰	MTX	116	49.1 ± 12.36	0.5 yr ± 0.488	76.72	87.93	94.8	NR	5.3 ± 1.3	NR	NR
Peterfy C (2016) ⁴⁶											
C-early	CTZ+MTX	660	50.5 ± 13.6	NR	75.6	NR	NR	NR	NR	NR	NR
C-early (2012) ¹⁶	MTX	219	51.3 ± 13.2	NR	79.9	NR	NR	NR	NR	NR	NR
C-OPERA	CTZ+MTX	161	49.4 ± 10.6	4 mo ± 2.9	81.1	NR	96.2	100	5.4 ± 1.1	5.2 ± 8.8 1.5*	NR
Atsumi T (2016) ¹⁷	MTX	158	49 ± 10.3	4.3 mo ± 2.8	80.9	NR	93	100	5.5 ± 1.2	6 ± 15.3 1.5*	NR
CAMERA-II	Pred+MTX	118	54 ± 14	NR	60	NR	55	NR	5.8 ± 1.3	0 (0-1)	NR
Bakker MF (2012) ²⁸	MTX	121	53 ± 13	NR	61	NR	61	NR	5.5 ± 1.1	0 (0-0)	NR
Landewe RB (2002) ²³											
COBRA	Pred+SSZ+MTX	76	49.5 ± 11.9	NR	66	NR	NR	NR	NR	NR	NR
Verhoeven AC (2000) ⁴⁷	SSZ	79	49.4 ± 12.3	NR	52	NR	NR	NR	NR	NR	NR

Trial Author Year	Abbreviated Name	Group N	Age, yr	Duration of RA	Gender, Female (%)	Race, Caucasian (%)	RF Positive n (%)	Anti-CCP Antibody Positive n (%)	DAS28	Total Sharp Score Modified Van der Heijde	Total Sharp Score Genant Modified
COBRA-light den Uyl D (2014) ¹⁹	Pred+SSZ+MTX	81	53 ± 13	22 wk ± 17	66.67	NR	58	61.73	5.55 ± 1.1	2.66 ± 6.5	NR
Ter Wee MM (2014) ³⁷	Pred+MTX	83	51 ± 12	25 wk ± 22	71.6	NR	59	67.9	5.32 ± 1.2	1.61 ± 4	NR
COMET Emery (2008) ¹²	ETN+MTX	274	50.5 ± 14.65	8.8 mo ± 6.51	74	87	NR	65.66	6.5 ± 1	NR	NR
Emery P (2010) ¹¹ Kekow J (2012) ¹³	MTX	268	52.3 ± 12.97	9.3 mo ± 6.49	73	88	NR	68.06	6.5 ± 1	NR	NR
FIN-RAco Mottonen T (1999) ²⁴	HCQ+Pred+SSZ+MTX	99	47	7.3 mo	58	NR	70	NR	5.39 ± 0.86	NR	NR
Mäkinen H (2007) ⁴⁸ Rantalaiho V (2009) ⁴⁹	SSZ	100	48	8.6 mo	66	NR	66	NR	5.65 ± 1.13	NR	NR
FUNCTION	TCZP+MTX	581	NR	NR	78.89	NR	89.79	86.28	NR	NR	NR
Burmester GR (2016) ¹⁵	MTX	289	49.6 ± 13.1	0.4 yr ± 0.48	80	NR	89	86	6.6 ± 0.99 6.5*	5.66 ± 14.581 1.5*	NR
Burmester GR (2017) ³⁶	TCZ4+MTX	290	51.2 ± 13.84	0.4 yr ± 0.49	79	NR	89	86	6.7 ± 1.05 6.7*	7.72 ± 17.155 2*	NR
Function ⁵⁰⁻⁵²	TCZ8+MTX	291	49.5 ± 13.7	0.5 yr ± 0.53	79	NR	91	87	6.7 ± 1.11 6.8*	6.17 ± 11.078 2*	NR

Trial Author Year	Abbreviated Name	Group N	Age, yr	Duration of RA	Gender, Female (%)	Race, Caucasian (%)	RF Positive n (%)	Anti-CCP Antibody Positive n (%)	DAS28	Total Sharp Score Modified Van der Heijde	Total Sharp Score Genant Modified
	TCZ8	292	49.9 ± 13.22	0.5 yr ± 0.48	75	NR	90	86	6.7 ± 0.99 6.7*	6.85 ± 16.1 1.5*	NR
HIT HARD	ADA+MTX	87	47.2 ± 12.12	1.8 mo ± 2.09	70.1	NR	63.2	NR	6.2 ± 0.86	6.3 ± 5	NR
Detert J (2013) ²⁹	MTX	85	52.5 ± 14.34	1.6 mo ± 1.7	67.1	NR	69.4	NR	6.3 ± 0.9	11.4 ± 14.8	NR
HOPEFUL-1	ADA+MTX	171	54 ± 13.1	0.3 yr ± 0.4	84.2	NR	85.4	84.8	6.6 ± 0.9	NR	NR
Takeuchi T (2013) ³⁵	MTX	163	54 ± 13.2	0.3 yr ± 0.4	78.5	NR	83.4	83.4	6.6 ± 1	NR	NR
Yamanaka H (2014) ⁵³											
IDEA	IFX+MTX	55	53.7 ± 13	1.2 mo (0.7- 1.7)	65.5	NR	49.1	NR	NR	6.05 ± 10.83	NR
Nam JL (2013) ²⁵	MPred+MTX	57	52.9 ± 12.8	1.2 mo (0.7- 2.1)	71.9	NR	60.7	NR	NR	9.23 ± 18.31	NR
OPERA	ADA+MTX	89	56.2*	88 d*	63	NR	70	60	5.5*	NR	NR
Hørslev-Petersen K (2014) ²¹											
Krintel SB (2015) ⁵⁴	MTX	91	54.2*	83 d*	69	NR	74	70	5.6*	NR	NR
Hørslev-Petersen K (2016) ³⁸											
OPTIMA	ADA+MTX	515	50.7 ± 14.5	4 mo ± 3.6	74	89	87	84	NR	11.8 ± 18.1	NR
Kavanaugh A	MTX	517	50.4 ± 13.6	4.5 mo ± 7.2	74	90	89	84	NR	11.2 ± 17.4	NR

Trial Author Year	Abbreviated Name	Group N	Age, yr	Duration of RA	Gender, Female (%)	Race, Caucasian (%)	RF Positive n (%)	Anti-CCP Antibody Positive n (%)	DAS28	Total Sharp Score Modified Van der Heijde	Total Sharp Score Genant Modified
(2012) ²²											
ORAL Start	MTX	107	NR	NR	NR	NR	NR	NR	NR	NR	NR
Fleischmann R.	TOF10	207	NR	NR	NR	NR	NR	NR	NR	NR	NR
(2015) ³²	TOF5	201	NR	NR	NR	NR	NR	NR	NR	NR	NR
PROWD	ADA+MTX	75	47 ± 9	9.5 mo ± 6	58.4	NR	96	63	5.9 ± 1.4	NR	NR
Bejarano V (2008) ⁷	MTX	73	47 ± 9	7.9 mo ± 5.4	53.4	NR	95	64	6 ± 1.5	NR	NR
Swefot	IFX+MTX	128	51.1 ± 13.3	6.2 mo ± 3.5	62	NR	69	NR	5.91 ± 0.93	4.57 ± 7.26	NR
van Vollenhoven RF											
(2009) ²⁷	HCQ+MTX+SSZ	130	52.9 ± 13.9	6.3 mo ± 3.6	78	NR	65	NR	5.98 ± 0.96	5.48 ± 9.39	NR
van Vollenhoven RF											
(2012) ³⁹											
U-Act-Early	MTX	108	53.5 (44.5-62)	27 d (15-46)	64	96	80	78	5.1 ± 1.2	0 (0-1)	NR
Bijlsma JWJ (2016) ⁹	TCZ+MTX	106	53 (46-60)	24.5 d (16-41.5)	61	94	71	68	5.2 ± 1.1	0 (0-1)	NR
Teitsma XM (2017) ¹⁰	TCZ	103	55 (47-63)	25.5 d (18-45)	76	97	66	65	5.3 ± 1.1	0 (0-1)	NR
Conaghan PG	MTX	37	47.8 ± 11.6	0.6 yr	78.4	NR	73	81.08	NR	13.7 ± 26	NR
(2016) ¹⁸	TOF+MTX	36	47.8 ± 12.3	0.8 yr	86.1	NR	76.5	79.4	NR	13 ± 21.7	NR
Unknown (2010) ⁴¹	TOF	36	50.8 ± 12.8	0.8 yr	83.3	NR	77.1	77.1	NR	12.6 ± 26	NR
Dougados M	MTX	69	50 ± 16.61	2.3 mo ± 2.49	74	NR	62	NR	NR	8.3	NR
(1999) ³⁰	SSZ+MTX	72	52 ± 16.49	3.4 mo ± 2.47	77	NR	71	NR	NR	8.91	NR

Trial Author Year	Abbreviated Name	Group N	Age, yr	Duration of RA	Gender, Female (%)	Race, Caucasian (%)	RF Positive n (%)	Anti-CCP Antibody Positive n (%)	DAS28	Total Sharp Score Modified Van der Heijde	Total Sharp Score Genant Modified
	SSZ	68	52 ± 16.49	2.9 mo ± 2.47	71	NR	75	NR	NR	6.11	NR
Durez P (2007) ³¹	IFX+MTX	15	50 ± 9.9	0.36 yr ± 0.31	67	NR	67	NR	5.3 ± 1.1	NR	NR
	MTX	14	53.8 ± 15.2	0.45 yr ± 0.29	71	NR	64	NR	5.2 ± 0.8	NR	NR
	MPred+MTX	15	50.3 ± 14.2	0.25 yr ± 0.33	60	NR	100	NR	5.3 ± 1.3	NR	NR
Fedorenko E. (2017) ⁸	Lefl	37	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Pred+MTX	34	NR	NR	NR	NR	NR	NR	NR	NR	NR
	MTX	35	NR	NR	NR	NR	NR	NR	NR	NR	NR
	MPred+Pred+MTX	35	NR	NR	NR	NR	NR	NR	NR	NR	NR
Islam MN (2000) ⁵	MTX	27	32.35 ± 14.79	NR	82.61	NR	NR	NR	NR	NR	NR
	SSZ+MTX	27	39.74 ± 11.08	NR	78.95	NR	NR	NR	NR	NR	NR
Marcora SM (2006) ³³	ETN	12	54 ± 11	NR	75	NR	58.33	NR	6.1 ± 0.7	NR	NR
	MTX	14	50 ± 15	NR	64.29	NR	58.33	NR	5.8 ± 1.1	NR	NR
Montecucco C (2012) ⁶	Pred+MTX	110	57 (45-67)	2.97 mo (1.93-5.1)	71.72	NR	NR	NR	5 (4.2-5.9)	NR	NR
	MTX	110	62 (51.5-72)	3.48 mo (2.57-5.7)	75	NR	NR	NR	5.2 (4.4-5.9)	NR	NR
Quinn MA (2005) ²⁶	IFX+MTX	10	51.3 ± 9.5	7.4 mo ± 4.6	NR	NR	70	NR	6.3 (5.9-6.8)	NR	NR
	MTX	10	53.1 ± 13.7	6 mo ± 3.7	NR	NR	60	NR	7 (6.4-7.6)	NR	NR
Svensson B (2003) ¹⁴	Pred	131	54 (47-63)	6 mo (4-10)	59	NR	71	NR	5 (4.2-5.9)	NR	NR
	SSZ	114	52 (43-67)	7 mo (4-10)	67	NR	39	NR	4.9 (4.5-5.8)	NR	NR

Trial Author Year	Abbreviated Name	Group N	Age, yr	Duration of RA	Gender, Female (%)	Race, Caucasian (%)	RF Positive n (%)	Anti-CCP Antibody Positive n (%)	DAS28	Total Sharp Score Modified Van der Heijde	Total Sharp Score Genant Modified
Data are mean ± SD or median (IQR). * indicates median where variance was not reported. ABA = abatacept; ADA = adalimumab; CTZ = certolizumab; ETN = etanercept; HCQ = hydroxychloroquine; IFX = infliximab; Lefl = leflunomide; MPred = methylprednisolone; MTX = methotrexate; Pred = prednisone; SSZ = sulfasalazine; TCZ = tocilizumab; TOF = tofacitinib											

Table 5 Characteristics of Studies Excluded from NMA

Trial Author Year	Abbreviated Name	Group N	Age, yr	Duration of RA	Gender, Female (%)	Race, Caucasian (%)	RF Positive n (%)	Anti-CCP Antibody Positive n (%)	DAS28	Total Sharp Score Modified Van der Heijde	Total Sharp Score Genant Modified
AGREE Smolen JS (2015) Westhovens R (2009)	ABA+MTX	256	49.4 ± 12.5	6.2 mo ± 7.5	75.2	NR	96.1	92.2	6.3 ± 1	NR	7.5 ± 9.7
	MTX	253	49.2 ± 12.8	7.1 mo ± 7.2	80.4	NR	96.8	85.8	6.2 ± 1	NR	6.7 ± 8.8
ARCTIC											
Moholt E (2016) Moholt E (2015)	DMARD	205	52.2 ± 13.4	NR	61.5	NR	NR	NR	NR	NR	NR
CareRA Verschuieren P (2015)	Lefl10-20+Pred+MTX	94	51.2 ± 12.8	3.1 wk ± 6.3	69.1	NR	75.5	NR	CRP: 4.7 ± 1.2 ESR: 5 ± 1.3	NR	NR
	Lefl10+Pred+MTX	98	51.8 ± 13.1	2.6 wk ± 3.3	64.3	NR	83.7	NR	CRP: 4.9 ± 1.1 ESR: 5.2 ± 1.2	NR	NR
	Pred+SSZ+MTX	98	53.2 ± 11.9	1.8 wk ± 3.1	65.3	NR	79.6	NR	CRP: 5 ± 1.2 ESR: 5.4 ± 1.3	NR	NR
CLEAR1 Conn DL (2018)	Pred10	238	50.8 ± 13.3	NR	80.3	NR	NR	NR	NR	NR	NR
	Pred5	107	51.4 ± 13.6	NR	86	NR	NR	NR	NR	NR	NR
CONCERTO Burmeister GR (2015) CONCERTO (2010)	ADA+MTX10	99	52.1 ± 12.94	NR	78.79	NR	82.8	81.8	NR	NR	NR
	ADA+MTX2.5	98	52 ± 13.19	NR	71.43	NR	86.7	77.6	NR	NR	NR
	ADA+MTX20	98	53.8 ± 14.41	NR	75.51	NR	81.6	82.7	NR	NR	NR
	ADA+MTX5	100	49.7 ± 13.14	NR	78	NR	83	77	NR	NR	NR

Trial Author Year	Abbreviated Name	Group N	Age, yr	Duration of RA	Gender, Female (%)	Race, Caucasian (%)	RF Positive n (%)	Anti-CCP Antibody Positive n (%)	DAS28	Total Sharp Score Modified Van der Heijde	Total Sharp Score Genant Modified
Corrona Pappas D.A. (2016)	Pred4.8	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
	Pred10-60	NR	NR	NR	NR	NR	NR	NR	NR	NR	NR
DREAM Vermeer M (2011)	MTX	534	58.6 ± 14.1	14 wk ± 13.33	62.4	NR	60.7	57.6	5 ± 1.1	2 ± 3.7	NR
ESPOIR Gaujoux-Viala C (2017)	MTX	76	44.5 ± 12.6	8.8 mo ± 9.7	73.7	NR	64.5	63.2	5.3 ± 1.3	NR	NR
GREAT Registry Hodkinson B (2012)	csDMARD+/-Pred	171	47 ± 12.5	11.6 mo ± 7	82	89	85	81	NR	NR	NR
HAWK Tanaka Y. (2017)	ADA+MTX	293	54.3 ± 13.9	12.1 mo ± 6.2	73	NR	NR	NR	4.5 ± 0.9	NR	NR
HOPEFUL-2 Tanaka Y (2016)	ADA+MTX	92	55.1 ± 13.5	1.3 yr ± 0.4	84.8	NR	56.5	NR	CRP: 2.2 ± 0.9 ESR: 2.9 ± 1.1	NR	NR
	MTX	96	53.4 ± 11.7	1.3 yr ± 0.4	83.3	NR	61.5	NR	CRP: 2.1 ± 0.9 ESR: 2.7 ± 1	NR	NR
NEO-RACo Leirisalo-Repo M (2012)	HCQ+Pred+SSZ+MTX	49	46 ± 11	4 mo ± 2.22	63.27	NR	73	NR	5.6 ± 1.4	2 ± 4.5	NR
	HCQ+IFX+Pred+SSZ+MTX	50	47 ± 10	4 mo ± 2.96	70	NR	78	NR	5.5 ± 1	2.8 ± 7.8	NR
NOR-DMARD Lie E (2012)	MTX	880	56.1 ± 13.3	NR	68.2	NR	61.5	NR	5.01 ± 1.36	NR	NR
	SSZ	150	49.7 ± 15.2	NR	64.7	NR	50.7	NR	4.35 ± 1.4	NR	NR

Trial Author Year	Abbreviated Name	Group N	Age, yr	Duration of RA	Gender, Female (%)	Race, Caucasian (%)	RF Positive n (%)	Anti-CCP Antibody Positive n (%)	DAS28	Total Sharp Score Modified Van der Heijde	Total Sharp Score Genant Modified
PRIZE Wiland P (2016)	ETN+MTX	193	NR	NR	NR	NR	NR	NR	NR	NR	NR
RADICAL Ermakova YA (2015)	DMARD	200	49 ± 13.33	NR	86.5	NR	67.5	57	5.1 ± 1.01	NR	NR
REMARCA Gridneva GI (2015)	MTX	237	NR	NR	NR	NR	NR	NR	NR	NR	NR
	MTX {Rheumatoid Arthritis ≤ 6 mo}	101	NR	NR	NR	NR	NR	NR	NR	NR	NR
SCQM Mueller R.B. (2016)	csDMARD+GC	363	55.1 ± 14.8	171.2 d ± 98.5	70.8	NR	63.6	62	4.6 ± 1.6	NR	NR
	csDMARD	228	51.3 ± 15.2	186.9 d ± 94.5	75.44	NR	68.9	65.3	4.3 ± 1.6	NR	NR
SWEFOT Saevarsdottir S (2010)	MTX	405	57 ± 14.81	6 mo ± 2.96	79	NR	49	64	5.7 ± 1.04	NR	NR
YEAR Conaghan PG (2010)	MTX+SSZ	194	59.2 ± 12.1	6.3 mo ± 3.7	68.6	96.4	72.1	NR	NR	NR	NR
Aydin Tufan M. (2014)	Pred+SSZ+MTX12.5	NR	NR	NR	NR	NR	NR	NR	6.51	NR	NR
	Pred+SSZ+MTX12.5-25	NR	NR	NR	NR	NR	NR	NR	6.05	NR	NR
Benaglio F. (2017)	GC_MTX10-20	123	NR	NR	NR	NR	NR	NR	5.2 ± 1.15	NR	NR
	GC_MTX15-25	137	NR	NR	NR	NR	NR	NR	4.6 ± 1.16	NR	NR
Conaghan PG (2003)	CS+MPred+MTX	22	53	5 mo*	61.9	NR	23.81	NR	NR	NR	NR
	CS+MTX	20	55	6 mo*	47.37	NR	68.42	NR	NR	NR	NR

[illegible]

Trial Author Year	Abbreviated Name	Group N	Age, yr	Duration of RA	Gender, Female (%)	Race, Caucasian (%)	RF Positive n (%)	Anti-CCP Antibody Positive n (%)	DAS28	Total Sharp Score Modified Van der Heijde	Total Sharp Score Genant Modified
Wick MC (2005)	MTX	114	NR	NR	NR	NR	NR	NR	NR	NR	NR
	MTX	56	63.4 ± 13	6.8 mo ± 3.9	71	NR	NR	NR	5.4 ± 1.1	NR	NR
	SSZ	55	53.6 ± 15.9	6.5 mo ± 3.6	56	NR	NR	NR	4.8 ± 1.1	NR	NR
Data are mean ± SD or median (IQR). * indicates median where variance was not reported. ABA = abatacept; ADA = adalimumab; bDMARD = biologic disease modifying anti-rheumatic drug; CRP = C-reactive protein; CS = corticosteroid; csDMARD = conventional synthetic disease modifying anti-rheumatic drug; CTZ = certolizumab; ESR = erythrocyte sedimentation rate; ETN = etanercept; GC = glucocorticoid; HCQ = hydroxychloroquine; IFX = infliximab; Lefl = leflunomide; MPred = methylprednisolone; MTX = methotrexate; Pred = prednisone; SSZ = sulfasalazine; TCZ = tocilizumab; TOF = tofacitinib											

Table 6 Outcomes of Studies Excluded from NMA

Trial Author Year	Abbreviated Name	N	Timepoint	ACR50 n (%)	DAS28 Remission n (%)	Total Withdrawal n (%)	AE Withdrawal n (%)
AGREE Smolen JS (2015) Westhovens R (2009)	ABA+MTX	256	6 mo	NR	94 (36.7%) 66 (31.4%) (N=210)	NR	NR
			1 yr	147 (57.4%)	106 (41.4%) 100 (47.6%) (N=210)	24 (9.38%)	7 (3.5%)
			6 mo	NR	51 (20.2%) 37 (17.7%) (N=209)	NR	NR
	MTX	253	6 mo	NR	51 (20.2%) 37 (17.7%) (N=209)	NR	NR
			1 yr	107 (42.3%)	59 (23.3%) 57 (27.3%) (N=209)	26 (10.28%)	9 (4.3%)
ARCTIC							
Moholt E (2016)	DMARD	205	1 yr	NR	NR	NR	NR
Moholt E (2015)							
CareRA Verschuere P (2015)	Lefl10-20+Pred+MTX	94	16 wk	NR	64 (68.1%)	3 (3.19%)	NR
	Lefl10+Pred+MTX	98	16 wk	NR	72 (73.5%)	2 (2.04%)	NR
	Pred+SSZ+MTX	98	16 wk	NR	69 (70.4%)	7 (7.14%)	NR
CLEAR1							
	Pred10	238	5 yr	NR	NR	111 (46.64%)	NR
Conn DL (2018)	Pred5	107	5 yr	NR	NR	47 (43.93%)	NR
CONCERTO							
	ADA+MTX10	99	6 mo	53 (54%)	37 (37%)	6 (6.1%)	2 (2.02%)
Burmester GR (2015)	ADA+MTX2.5	98	6 mo	46 (47%)	26 (27%)	15 (15.3%)	3 (3.06%)

Trial Author Year	Abbreviated Name	N	Timepoint	ACR50 n (%)	DAS28 Remission n (%)	Total Withdrawal n (%)	AE Withdrawal n (%)
CONCERTO (2010)	ADA+MTX20	98	6 mo	62 (63%)	44 (45%)	9 (9.2%)	3 (3.06%)
	ADA+MTX5	100	6 mo	49 (49%)	32 (32%)	7 (7%)	0 (0%)
Corrona	Pred4.8	NR	NR	NR	NR	NR	NR
Pappas D.A. (2016)	Pred10-60	NR	NR	NR	NR	NR	NR
DREAM							
Vermeer M (2011)	MTX	389	1 yr	NR	226 (58.1%)	NR	NR
ESPOIR							
Gaujoux-Viala C (2017)	MTX	76	2 yr	NR	40 (52.63%)	NR	NR
GREAT Registry							
Hodkinson B (2012)	csDMARD+/-Pred	171	NR	NR	NR	NR	NR
HAWK							
Tanaka Y. (2017)	ADA+MTX	293	1 yr	NR	226 (77%)	NR	NR
HOPEFUL-2							
Tanaka Y (2016)	ADA+MTX	92	1 yr	NR	70 (76.1%)	NR	NR
	MTX	96	1 yr	NR	58 (60.4%)	NR	NR
NEO-RACo	HCQ+Pred+SSZ+MTX	49	6 mo	NR	44 (89.8%)	NR	NR
			2 yr	45 (92%)	40 (82%)	4 (8.16%)	0 (0%)
	HCQ+IFX+Pred+SSZ+MTX	50	6 mo	NR	46 (92.1%)	NR	NR
			2 yr	48 (96%)	41 (82%)	4 (8%)	1 (2%)
Leirisalo-Repo M (2012)							
NOR-DMARD	MTX	743	6 mo	186 (25.1%)	241 (32.5%)	NR	NR

Trial Author Year	Abbreviated Name	N	Timepoint	ACR50 n (%)	DAS28 Remission n (%)	Total Withdrawal n (%)	AE Withdrawal n (%)
Lie E (2012)	SSZ	89	6 mo	15 (16.3%)	40 (44.7%)	NR	NR
PRIZE Wiland P (2016)	ETN+MTX	193	1 yr	NR	NR	NR	NR
RADICAL Ermakova YA (2015)	DMARD	200	5 yr	NR	NR	NR	NR
REMARCA Gridneva GI (2015)	MTX MTX {Rheumatoid Arthritis <= 6 mo}	237 101	NR NR	NR NR	NR NR	NR NR	NR NR
SCQM Mueller R.B. (2016)	csDMARD+GC csDMARD	363 228	5 yr 5 yr	NR NR	NR NR	NR NR	NR NR
SWEFOT Saevarsdottir S (2010)	MTX	395 395	4 mo 3 mo (minimum)	131 (33%) NR	NR 90 (22.78%)	NR NR	NR NR
YEAR Conaghan PG (2010)	MTX+SSZ	194	6 mo	NR	NR	NR	NR
Aydin Tufan M. (2014)	Pred+SSZ+MTX12.5 Pred+SSZ+MTX12.5-25	NR NR	3 mo 3 mo	NR NR	NR NR	NR NR	NR NR
Benaglio F. (2017)	GC_MTX10-20 GC_MTX15-25	123 137	6 mo 6 mo	NR NR	39 (32%) 55 (40%)	NR NR	NR NR
Conaghan PG (2003)	CS+MPred+MTX CS+MTX	22 20	1 yr 1 yr	NR NR	NR NR	NR NR	NR NR

Trial Author Year	Abbreviated Name	N	Timepoint	ACR50 n (%)	DAS28 Remission n (%)	Total Withdrawal n (%)	AE Withdrawal n (%)
Cummins L (2015)	HCQ+SSZ+MTX	119	1 yr	NR	12 (42%) (N=28)	NR	NR
	No Triple Therapy	62	1 yr	NR	NR	NR	NR
El-Barbary AM (2011)	Pred+MTX	100	1 yr	NR	NR	NR	NR
Gevers L.A.H.A. (2016)	HCQ+MTX	50	1 yr	NR	24 (48%)	NR	NR
	HCQ+/-MTX	38	1 yr	NR	10 (26%)	NR	NR
Gorbunova Y (2015)	bDMARD+MTX	40	6 mo	NR	9 (22.5%)	NR	NR
	MTX	34	6 mo	NR	16 (47%)	NR	NR
Kellner H (2010)	Lefl	334	6 mo	NR	65 (25%) (N=260)	NR	NR
Kovalchik SA (2011)	csDMARD	267	1 yr	NR	11 (7%) (N=152)	NR	NR
Lourida ES (2007)	Pred+MTX	58	1 yr	NR	NR	NR	NR
Matchanov S.X. (2017)	Lefl+MTX	40	6 mo	NR	NR	NR	NR
	MTX	40	6 mo	NR	NR	NR	NR
Matteson EL (2004)	HCQ	111	2 yr	85 (90.43%) (N=94)	NR	17 (15.32%)	NR
Ren LM (2015)	Lefl10	118	6 mo	NR	NR	39 (33%)	5 (4.2%)
	Lefl50	126	6 mo	NR	NR	34 (27%)	4 (3.2%)
van Jaarsveld CH (2000)	HCQ	120	4 yr	NR	NR	NR	NR
	MTX	114	4 yr	NR	NR	NR	NR
Wick MC (2005)	MTX	56	1 yr	NR	NR	NR	NR
	SSZ	55	1 yr	NR	NR	NR	NR

Trial Author Year	Abbreviated Name	N	Timepoint	ACR50 n (%)	DAS28 Remission n (%)	Total Withdrawal n (%)	AE Withdrawal n (%)
Data are reported as n(%).ADA = adalimumab; bDMARD = biologic disease modifying anti-rheumatic drug; CRP = C-reactive protein; CS = corticosteroid; csDMARD = conventional synthetic disease modifying anti-rheumatic drug; CTZ = certolizumab; ESR = erythrocyte sedimentation rate; ETN = etanercept; GC = glucocorticoid; HCQ = hydroxychloroquine; IFX = infliximab; Lefl = leflunomide; MPred = methylprednisolone; MTX = methotrexate; Pred = prednisone; SSZ = sulfasalazine; TCZ = tocilizumab; TOF = tofacitinib; ACR = American College of Rheumatology; DAS28 = Disease Activity Score in 28 Joints; AE = adverse event							

Table 7 Risk of Bias Summary for Analyzed Studies

[illegible]

Author Year	Selection bias		Performance bias	Detection bias	Attrition bias	Reporting bias	Other bias
	Random sequence generation	Allocation concealment	Blinding of participants and personnel	Blinding of outcome assessment	Incomplete outcome data	Selective reporting	Other sources of bias
Marcora SM (2006)	Unclear risk	High risk	High risk	Low risk	Low risk	Low risk	Low risk
Montecucco C (2012)	Low risk	Unclear risk	High risk	Low risk	Low risk	Low risk	Low risk
Mottonen T (1999)	Low risk	Low risk	High risk	High risk	Low risk	Low risk	Low risk
C-early (2012)	Low risk	Low risk	Low risk	Unclear risk	Low risk	Low risk	Low risk
Nam JL (2013)	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk	Low risk
Quinn MA (2005)	Low risk	Unclear risk	Unclear risk	Low risk	Low risk	Low risk	Low risk
Schiff M (2014)	Unclear risk	Unclear risk	High risk	Unclear risk	Low risk	Low risk	Low risk
Svensson B (2003)	Unclear risk	Unclear risk	High risk	High risk	Low risk	Low risk	Low risk
Takeuchi T (2013)	Unclear risk	Unclear risk	Unclear risk	Low risk	Low risk	Low risk	Low risk
van Vollenhoven RF (2009)	Low risk	Low risk	High risk	High risk	Low risk	Low risk	Low risk

Table 8 Outcomes of Studies Included in NMA

Trial				ACR50	DAS28 Remission	Total Withdrawal	AE Withdrawal
Author Year	Abbreviated Name	Timepoint	N	n (%)	n (%)	n (%)	n (%)
Schiff M. (2014)	ABA+MTX	6 mo	71	31 (43.5%)	19 (26.8%)	NR	NR
		1 yr	71	35 (49.4%)	32 (45.1%)	NR	NR
		2 yr	71	30 (42.3%)	30 (42.6%)	17 (23.9%)	2 (2.8%)
	ADA+MTX	6 mo	70	22 (31.3%)	16 (22.9%)	NR	NR
		1 yr	70	26 (36.9%)	20 (28.6%)	NR	NR
		2 yr	70	26 (37.1%)	36 (51%)	21 (30.0%)	8 (11.4%)
AVERT (2010)	ABA+MTX	6 mo	119	73 (61.3%)	62 (52.1%)	NR	NR
		1 yr	119	75 (63%)	70 (60.9%) (N=115)	16 (13.5%)	5 (4.2%)
	ABA	6 mo	116	56 (48.3%)	42 (36.2%)	NR	NR
		1 yr	116	62 (53.4%)	48 (42.5%) (N=113)	25 (21.6%)	8 (6.9%)
	MTX	6 mo	116	43 (37%)	30 (25.9%)	NR	NR
		1 yr	116	54 (46.6%)	52 (45.2%) (N=115)	20 (17.2%)	5 (4.3%)
C-early (2012)	CTZ+MTX	1 yr	655	405 (61.8%)	279 (42.6%)	368 (56.2%)	54 (8.2%)
C-early (2012)	MTX	1 yr	213	112 (52.6%)	57 (26.8%)	152 (71.4%)	20 (9.4%)
Atsumi T (2016)	CTZ+MTX	6 mo	159	109 (68.6%)	84 (52.8%)	NR	NR
		1 yr	159	116 (73%)	91 (57.2%)	48 (30.2%)	9 (5.7%)
	MTX	6 mo	157	83 (52.9%)	48 (30.6%)	NR	NR
		1 yr	157	81 (51.6%)	58 (36.9%)	84 (53.5%)	6 (3.8%)

Trial	Abbreviated Name	Timepoint	N	ACR50	DAS28 Remission	Total Withdrawal	AE Withdrawal
Author Year				n (%)	n (%)	n (%)	n (%)
CAMERA-II Bakker MF (2012)	Pred+MTX	1 yr	117	66 (56%)	NR	NR	NR
		2 yr	117	62 (53%)	NR	32 (27.4%)	16 (14%)
	MTX	1 yr	119	51 (43%)	NR	NR	NR
		2 yr	119	50 (42%)	NR	34 (28.6%)	20 (17%)
COBRA Verhoeven AC (2000) Landewe RB (2002)	Pred+SSZ+MTX	28 wk	76	37 (49%)	13 (17%)	NR	NR
	SSZ	28 wk	79	21 (27%)	8 (10%)	NR	NR
COBRA-light den Uyl D (2014) Ter Wee MM (2014)	Pred+SSZ+MTX	6 mo	81	46 (57%)	NR	NR	NR
		1 yr	81	20 (25%)	NR	3 (3.7%)	2 (2.5%)
	Pred+MTX	6 mo	81	50 (62%)	NR	NR	NR
		1 yr	81	14 (17%)	NR	4 (4.9%)	1 (1.2%)
COMET Emery P (2008) Emery P (2010) Kekow J (2010)	ETN+MTX	6 mo	265	NR	110 (41.5%)	NR	NR
		1 yr	274	181 (71%) (N=256)	132 (50%) (N=265)	53 (19.3%)	28 (10.2%)
		2 yr	111	76 (70%) (N=108)	62 (57.4%) (N=108)	7 (6%)	3 (3%)
	MTX	6 mo	263	NR	62 (23.6%)	NR	NR
		1 yr	268	119 (49%) (N=243)	73 (28.0%) (N=263)	79 (29.5%)	34 (12.7%)
		2 yr	99	43 (46%) (N=94)	33 (35.1%) (N=94)	23 (23%)	9 (9%)
FIN-Raco	HCCQ+Pred+SSZ+MTX	6 mo	97	68 (69.1%)	41 (51.5%) (N=79)	NR	NR

Trial				ACR50	DAS28 Remission	Total Withdrawal	AE Withdrawal
Author Year	Abbreviated Name	Timepoint	N	n (%)	n (%)	n (%)	n (%)
Mottonen T (1999)		1 yr	97	74 (74.6%)	42 (53.6%) (N=79)	NR	NR
Mäkinen H (2007)		2 yr	97	66 (75.9%) (N=87)	54 (68%) (N=79)	10 (10.3%)	0 (0%)
Rantalaaho V (2009)		6 mo	98	58 (57.6%)	30 (33.2%) (N=90)	NR	NR
	SSZ	1 yr	98	59 (58.8%)	27 (29.5%) (N=90)	NR	NR
		2 yr	98	52 (57.1%) (N=91)	37 (41%) (N=90)	7 (7.1%)	0 (0%)
		6 mo	287	124 (43.0%)	43 (15.0%)	NR	NR
	MTX	1 yr	287	119 (41.03%)	56 (19.5%)	63 (21.8%) (N=289)	21 (7.4%) (N=282)
		2 yr	287	64 (22.0%)	46 (16.0%)	NR	NR
		6 mo	288	139 (48.1%)	92 (31.9%)	NR	NR
FUNCTION	TCZ4+MTX	1 yr	288	146 (50.25%)	98 (34.0%)	59 (20.3%) (N=290)	35 (12.1%) (N=289)
Burmester GR (2016)		2 yr	288	106 (36.5%)	81 (28.1%)	NR	NR
Burmester GR (2017)		6 mo	290	166 (57.1%)	130 (44.8%)	NR	NR
	TCZ8+MTX	1 yr	290	164 (56.28%)	142 (49.0%)	64 (22.0%) (N=291)	59 (20.3%)
		2 yr	290	168 (57.6%)	138 (47.6%)	NR	NR
		6 mo	292	140 (47.8%)	113 (38.7%)	NR	NR
	TCZ8	1 yr	292	145 (49.6%)	115 (39.4%)	56 (19.2%)	34 (11.6%)
		2 yr	292	155 (53.1%)	127 (43.5%)	NR	NR
HIT HARD		6 mo	87	56 (64.4%)	42 (48.3%)	5 (5.8%)	2 (2.3%)
	ADA+MTX						
Detert J (2013)		1 yr	87	46 (52.9%)	37 (42.4%)	11 (12.6%)	4 (4.6%)

Trial				ACR50	DAS28 Remission	Total Withdrawal	AE Withdrawal
Author Year	Abbreviated Name	Timepoint	N	n (%)	n (%)	n (%)	n (%)
	MTX	6 mo	85	41 (48.2%)	25 (29.4%)	12 (14.1%)	4 (4.7%)
		1 yr	85	44 (51.8%)	31 (36.8%)	28 (32.9%)	7 (8.2%)
HOPEFUL-1	ADA+MTX	6 mo	171	110 (64.3%)	89 (52%)	15 (8.8%) (N=170)	7 (4.1%) (N=170)
Takeuchi T (2013)	MTX	6 mo	163	63 (38.7%)	43 (26.4%)	12 (7.4%)	5 (3.1%)
Yamanaka H (2014)							
IDEA	IFX+MTX	6 mo	55	30 (54%)	21 (41.2%) (N=51)	NR	NR
Nam JL (2013)	MPred+MTX	6 mo	57	31 (55.1%)	28 (50.9%) (N=55)	NR	NR
OPERA	ADA+MTX	6 mo	89	NR	55 (62%)	NR	NR
Hørslev-Petersen K (2014)		1 yr	89	71 (80%) (N=85)	66 (74%)	8 (9.0%)	2 (2.3%)
Krintel SB (2015)	MTX	6 mo	91	NR	42 (46%)	NR	NR
Hørslev-Petersen K (2016)		1 yr	91	57 (63%) (N=83)	45 (49%)	11 (12.1%)	1 (1.1%)
OPTIMA	ADA+MTX	6 mo	515	268 (52%)	175 (34%)	49 (10%)	21 (4%)
Kavanaugh A (2012)	MTX	6 mo	517	177 (34.2%)	88 (17%)	57 (11%)	16 (3%)
ORAL Start	MTX	1 yr	107	32 (29.9%)	10 (9.3%)	NR	NR
		2 yr	107	34 (31.8%)	12 (11.2%)	NR	14 (13.1%)
	TOF10	1 yr	207	120 (57.9%)	51 (24.6%)	NR	NR
		2 yr	207	110 (53.1%)	45 (21.7%)	NR	21 (10.1%)
	TOF5	2 yr	201	109 (54.2%)	50 (24.9%)	NR	NR

Trial				ACR50	DAS28 Remission	Total Withdrawal	AE Withdrawal
Author Year	Abbreviated Name	Timepoint	N	n (%)	n (%)	n (%)	n (%)
PROWD	ADA+MTX	1 yr	75	42 (56%)	36 (48%)	25 (33.3%)	5 (6.7%)
Bejarano V (2008)	MTX	1 yr	73	33 (45.2%)	26 (35.6%)	37 (50.7%)	5 (6.9%)
Swefot	IFX+MTX	1 yr	128	32 (25%)	NR	23 (18.0%)	10 (7.8%)
		2 yr	128	38 (30%)	NR	38 (29.7%)	19 (14.8%)
van Vollenhoven RF (2009)	HCQ+SSZ+MTX	1 yr	130	19 (15%)	NR	41 (31.5%)	14 (10.8%)
van Vollenhoven RF (2012)		2 yr	130	28 (22%)	NR	56 (43.1%)	22 (16.9%)
U-Act-Early	MTX	6 mo	106	36 (34%)	42 (39.6%)	NR	NR
		1 yr	103	53 (51%)	63 (61.2%)	NR	NR
		2 yr	108	48 (48%) (N=99)	58 (58.6%) (N=99)	30 (27.8%)	8 (7.4%)
	TCZ+MTX	6 mo	105	67 (64%)	84 (80%)	NR	NR
		1 yr	100	61 (62%) (N=99)	71 (71%)	NR	NR
		2 yr	106	47 (49%) (N=96)	71 (74%) (N=96)	28 (26.4%)	9 (8.5%)
		6 mo	102	60 (59%)	77 (75.5%)	NR	NR
	TCZ	1 yr	99	58 (59%)	80 (80.8%)	NR	NR
		2 yr	103	52 (55%) (N=95)	67 (70.5%) (N=95)	22 (21.4%)	10 (9.7%)
Conaghan PG (2016)	MTX	6 mo	37	10 (27%)	5 (13.5%)	NR	NR
		1 yr	37	11 (29.7%)	5 (13.5%)	16 (43.2%)	5 (13.5%)
Unknown (2010)	TOF+MTX	6 mo	36	20 (57.1%) (N=35)	10 (29.4%) (N=34)	NR	NR
		1 yr	36	23 (65.7%) (N=35)	11 (32.4%) (N=34)	8 (22.2%)	4 (11.1%)

Trial							
Author Year	Abbreviated Name	Timepoint	N	ACR50 n (%)	DAS28 Remission n (%)	Total Withdrawal n (%)	AE Withdrawal n (%)
	TOF	6 mo	36	19 (52.8%)	5 (13.9%)	NR	NR
		1 yr	36	18 (50%)	7 (19.4%)	9 (25%)	2 (5.6%)
	MTX	1 yr	69	NR	NR	15 (21.7%)	7 (10.1%)
	SSZ+MTX	1 yr	72	NR	NR	21 (29.2%)	9 (13.2%) (N=68)
	SSZ	1 yr	68	NR	NR	21 (30.9%)	10 (14.7%)
	IFX+MTX	6 mo	15	10 (66.7%)	NR	NR	NR
		1 yr	15	10 (66.7%)	NR	1 (6.7%)	1 (6.7%)
	MTX	6 mo	14	1 (7.1%)	NR	NR	NR
		1 yr	14	6 (42.9%)	NR	2 (14.3%)	0 (0%)
	MPred+MTX	6 mo	15	10 (66.7%)	NR	NR	NR
		1 yr	15	10 (66.7%)	NR	1 (6.7%)	0 (0%)
	Lefl	1 yr	NR	NR	NR	NR	4 (10.8%)
Fedorenko E. (2017)	Pred+MTX	1 yr	NR	NR	NR	NR	0 (0%)
	MTX	1 yr	NR	NR	NR	NR	1 (2.9%)
	MPred+Pred+MTX	1 yr	NR	NR	NR	NR	1 (2.9%)
Islam MN (2000)	MTX	6 mo	23	NR	NR	8 (34.8%)	1 (4.4%)
	SSZ+MTX	6 mo	19	NR	NR	4 (21.1%)	4 (21.1%)
Marcora SM (2006)	ETN	6 mo	12	NR	NR	0 (0%)	NR
	MTX	6 mo	12	NR	NR	1 (8.3%)	NR

Trial	Abbreviated Name	Timepoint	N	ACR50	DAS28 Remission	Total Withdrawal	AE Withdrawal
Author Year				n (%)	n (%)	n (%)	n (%)
Montecucco C (2012)	Pred+MTX	1 yr	96	NR	43 (44.8%)	NR	NR
	MTX	1 yr	90	NR	25 (27.8%)	NR	NR
Quinn MA (2005)	IFX+MTX	1 yr	10	8 (80%)	NR	1 (10%)	1 (10%)
	MTX	1 yr	10	4 (40%)	NR	0 (0%)	0 (0%)
Svensson B (2003)	Pred	2 yr	113	NR	33 (29%)	22 (19%)	13 (11.5%)
	SSZ	2 yr	108	NR	21 (19%)	51 (47%)	36 (33.3%)
Data are reported as n(%). ABA = abatacept; ADA = adalimumab; CTZ = certolizumab; ETN = etanercept; HCQ = hydroxychloroquine; IFX = infliximab; Lefl = leflunomide; MPred = methylprednisolone; MTX = methotrexate; Pred = prednisone; SSZ = sulfasalazine; TCZ = tocilizumab; TOF = tofacitinib; ACR = American College of Rheumatology; DAS28 = Disease Activity Score in 28 Joints; AE = adverse event							

Table 9 ACR50 League Table (Main Analysis)

SSZ	HCQ+ Pred+ SSZ+ MTX	MTX	Pred+ MTX	HCQ+ MTX+SSZ	CTZ+MTX	Pred+SSZ +MTX	ABA+ MTX	ADA+ MTX	TOF	ETN+ MTX	TCZ	TCZ+MTX	IFX+MTX	MPred+ MTX	TOF+ MTX	ABA
SSZ	0.75 (0.44, 1.3)	0.68 (0.27, 1.8)	0.54 (0.25, 1.2)	0.5 (0.14, 1.8)	0.52 (0.19, 1.5)	0.53 (0.27, 1)	0.46 (0.17, 1.3)	0.48 (0.19, 1.3)	0.49 (0.17, 1.5)	0.44 (0.15, 1.4)	0.41 (0.15, 1.2)	0.4 (0.15, 1.2)	0.37 (0.12, 1.1)	0.39 (0.12, 1.2)	0.38 (0.13, 1.2)	0.57 (0.2, 1.7)
1.3 (0.79, 2.3)	HCQ+ Pred+SSZ+ MTX	0.9 (0.31, 2.8)	0.73 (0.28, 2)	0.67 (0.17, 2.7)	0.7 (0.22, 2.3)	0.71 (0.3, 1.7)	0.63 (0.19, 2)	0.65 (0.21, 2.1)	0.66 (0.19, 2.3)	0.58 (0.18, 2.1)	0.54 (0.18, 1.9)	0.54 (0.17, 1.8)	0.5 (0.14, 1.8)	0.52 (0.14, 1.9)	0.5 (0.15, 1.7)	0.77 (0.23, 2.5)
1.5 (0.56, 3.7)	1.1 (0.35, 3.3)	MTX	0.8 (0.47, 1.4)	0.74 (0.3, 1.7)	0.78 (0.54, 1.1)	0.79 (0.38, 1.6)	0.69 (0.45, 1)	0.72 (0.57, 0.89)	0.73 (0.43, 1.2)	0.65 (0.37, 1.1)	0.6 (0.42, 0.88)	0.6 (0.42, 0.89)	0.56 (0.29, 0.99)	0.57 (0.29, 1.1)	0.56 (0.33, 0.91)	0.83 (0.51, 1.4)
1.8 (0.81, 4)	1.4 (0.5, 3.6)	1.2 (0.72, 2.1)	Pred+MTX	0.93 (0.32, 2.6)	0.97 (0.5, 1.8)	0.97 (0.63, 1.5)	0.86 (0.44, 1.7)	0.89 (0.49, 1.6)	0.9 (0.43, 1.9)	0.8 (0.36, 1.7)	0.75 (0.38, 1.5)	0.75 (0.39, 1.5)	0.69 (0.3, 1.5)	0.71 (0.3, 1.6)	0.69 (0.32, 1.4)	1 (0.5, 2.1)
2 (0.56, 7.4)	1.5 (0.37, 6)	1.3 (0.58, 3.3)	1.1 (0.39, 3.1)	HCQ+ MTX+SSZ	1 (0.41, 2.7)	1.1 (0.34, 3.2)	0.93 (0.35, 2.5)	0.97 (0.4, 2.4)	0.98 (0.36, 2.7)	0.87 (0.32, 2.4)	0.81 (0.33, 2.1)	0.81 (0.33, 2.1)	0.74 (0.4, 1.4)	0.77 (0.36, 1.6)	0.75 (0.28, 2.1)	1.1 (0.42, 3.1)
1.9 (0.67, 5.2)	1.4 (0.44, 4.6)	1.3 (0.91, 1.8)	1 (0.55, 2)	0.95 (0.37, 2.4)	CTZ+MTX	1 (0.44, 2.2)	0.89 (0.52, 1.5)	0.92 (0.62, 1.4)	0.93 (0.5, 1.7)	0.84 (0.44, 1.6)	0.78 (0.47, 1.3)	0.77 (0.46, 1.3)	0.72 (0.34, 1.4)	0.74 (0.33, 1.5)	0.72 (0.38, 1.3)	1.1 (0.58, 2)
1.9 (1, 3.7)	1.4 (0.6, 3.3)	1.3 (0.64, 2.7)	1 (0.67, 1.6)	0.94 (0.31, 2.9)	0.98 (0.46, 2.3)	Pred+SSZ+ MTX	0.88 (0.4, 2)	0.91 (0.45, 1.9)	0.92 (0.4, 2.2)	0.82 (0.34, 2.1)	0.76 (0.36, 1.8)	0.76 (0.35, 1.8)	0.7 (0.28, 1.8)	0.72 (0.28, 1.9)	0.71 (0.3, 1.7)	1.1 (0.46, 2.6)
2.2 (0.74, 5.9)	1.6 (0.49, 5.2)	1.4 (0.98, 2.2)	1.2 (0.61, 2.3)	1.1 (0.4, 2.8)	1.1 (0.66, 1.9)	1.1 (0.5, 2.5)	ABA+MTX	1 (0.7, 1.6)	1.1 (0.54, 2)	0.94 (0.48, 1.9)	0.87 (0.51, 1.6)	0.87 (0.52, 1.6)	0.8 (0.37, 1.7)	0.82 (0.37, 1.8)	0.8 (0.43, 1.5)	1.2 (0.75, 2)

SSZ	HCQ+ Pred+ SSZ+ MTX	MTX	Pred+ MTX	HCQ+ MTX+SSZ	CTZ+MTX	Pred+SSZ +MTX	ABA+ MTX	ADA+ MTX	TOF	ETN+ MTX	TCZ	TCZ+MTX	IFX+MTX	MPred+ MTX	TOF+ MTX	ABA
2.1 (0.77, 5.4)	1.5 (0.49, 4.7)	1.4 (1.1, 1.8)	1.1 (0.64, 2)	1 (0.42, 2.5)	1.1 (0.72, 1.6)	1.1 (0.51, 2.2)	0.97 (0.63, 1.4)	ADA+MTX	1 (0.57, 1.8)	0.9 (0.5, 1.6)	0.84 (0.54, 1.3)	0.84 (0.54, 1.3)	0.78 (0.39, 1.4)	0.8 (0.38, 1.6)	0.78 (0.44, 1.3)	1.2 (0.7, 2)
2 (0.67, 6)	1.5 (0.44, 5.3)	1.4 (0.83, 2.3)	1.1 (0.54, 2.3)	1 (0.37, 2.8)	1.1 (0.57, 2)	1.1 (0.45, 2.5)	0.95 (0.5, 1.9)	0.99 (0.57, 1.8)	TOF	0.89 (0.42, 1.9)	0.83 (0.44, 1.6)	0.84 (0.44, 1.6)	0.77 (0.33, 1.7)	0.8 (0.32, 1.8)	0.77 (0.48, 1.2)	1.2 (0.56, 2.3)
2.3 (0.71, 6.6)	1.7 (0.48, 5.7)	1.5 (0.9, 2.7)	1.2 (0.58, 2.8)	1.1 (0.41, 3.2)	1.2 (0.63, 2.3)	1.2 (0.48, 3)	1.1 (0.53, 2.1)	1.1 (0.61, 2)	1.1 (0.52, 2.4)	ETN+MTX	0.93 (0.49, 1.8)	0.93 (0.5, 1.8)	0.85 (0.37, 1.9)	0.89 (0.37, 2)	0.86 (0.41, 1.8)	1.3 (0.59, 2.7)
2.5 (0.85, 6.6)	1.9 (0.53, 5.5)	1.7 (1.1, 2.4)	1.3 (0.68, 2.7)	1.2 (0.48, 3.1)	1.3 (0.76, 2.1)	1.3 (0.55, 2.8)	1.1 (0.62, 1.9)	1.2 (0.77, 1.8)	1.2 (0.61, 2.3)	1.1 (0.56, 2)	TCZ	1 (0.7, 1.5)	0.92 (0.43, 1.8)	0.95 (0.42, 2)	0.92 (0.48, 1.7)	1.4 (0.73, 2.5)
2.5 (0.83, 6.5)	1.8 (0.54, 5.8)	1.7 (1.1, 2.4)	1.3 (0.69, 2.6)	1.2 (0.47, 3.1)	1.3 (0.76, 2.2)	1.3 (0.56, 2.8)	1.2 (0.64, 1.9)	1.2 (0.76, 1.8)	1.2 (0.62, 2.3)	1.1 (0.55, 2)	1 (0.69, 1.4)	TCZ+MTX	0.91 (0.43, 1.8)	0.95 (0.42, 2)	0.93 (0.46, 1.7)	1.4 (0.74, 2.6)
2.7 (0.88, 8.2)	2 (0.56, 7)	1.8 (1, 3.5)	1.5 (0.65, 3.4)	1.3 (0.74, 2.5)	1.4 (0.72, 2.9)	1.4 (0.55, 3.6)	1.2 (0.6, 2.7)	1.3 (0.7, 2.6)	1.3 (0.6, 3.1)	1.2 (0.54, 2.7)	1.1 (0.55, 2.3)	1.1 (0.56, 2.3)	IFX+MTX	1 (0.68, 1.6)	1 (0.46, 2.3)	1.5 (0.7, 3.5)
2.6 (0.82, 8.3)	1.9 (0.53, 7.2)	1.8 (0.92, 3.5)	1.4 (0.62, 3.3)	1.3 (0.61, 2.7)	1.4 (0.66, 3)	1.4 (0.53, 3.5)	1.2 (0.56, 2.7)	1.3 (0.63, 2.6)	1.3 (0.56, 3.1)	1.1 (0.5, 2.7)	1 (0.51, 2.4)	1.1 (0.5, 2.4)	0.97 (0.63, 1.5)	MPred+ MTX	0.97 (0.43, 2.3)	1.5 (0.65, 3.5)
2.7 (0.84, 7.8)	2 (0.58, 6.5)	1.8 (1.1, 3)	1.4 (0.71, 3.1)	1.3 (0.48, 3.6)	1.4 (0.76, 2.6)	1.4 (0.6, 3.3)	1.2 (0.66, 2.3)	1.3 (0.74, 2.3)	1.3 (0.83, 2.1)	1.2 (0.55, 2.4)	1.1 (0.58, 2.1)	1.1 (0.58, 2.2)	1 (0.43, 2.2)	1 (0.43, 2.4)	TOF+MTX	1.5 (0.75, 3.1)
1.8 (0.59, 4.9)	1.3 (0.39, 4.3)	1.2 (0.71, 2)	0.96 (0.47, 2)	0.89 (0.32, 2.4)	0.92 (0.51, 1.7)	0.94 (0.39, 2.2)	0.82 (0.5, 1.3)	0.86 (0.51, 1.4)	0.87 (0.43, 1.8)	0.77 (0.37, 1.7)	0.72 (0.39, 1.4)	0.72 (0.39, 1.4)	0.66 (0.29, 1.4)	0.68 (0.29, 1.5)	0.67 (0.32, 1.3)	ABA

Table 10 ACR50 League Table (Timepoint Sensitivity – 6 mo)

CTZ+MTX	TCZ	ABA	ADA+MTX	TCZ+MTX	ABA+MTX	TOF	TOF+MTX	IFX+MTX	MPred+MTX	MTX
CTZ+MTX	1 (0.63, 1.5)	0.93 (0.55, 1.6)	0.87 (0.58, 1.3)	0.88 (0.54, 1.3)	0.72 (0.44, 1.2)	0.69 (0.32, 1.5)	0.65 (0.3, 1.4)	0.085 (0.0041, 0.42)	0.089 (0.004, 0.43)	1.3 (0.91, 1.9)
0.99 (0.66, 1.6)	TCZ	0.93 (0.58, 1.5)	0.86 (0.63, 1.3)	0.87 (0.68, 1.1)	0.72 (0.47, 1.1)	0.7 (0.33, 1.4)	0.65 (0.31, 1.3)	0.086 (0.0039, 0.43)	0.088 (0.004, 0.43)	1.3 (1, 1.8)
1.1 (0.62, 1.8)	1.1 (0.65, 1.7)	ABA	0.93 (0.61, 1.5)	0.93 (0.56, 1.5)	0.77 (0.52, 1.1)	0.75 (0.34, 1.6)	0.7 (0.31, 1.5)	0.093 (0.0042, 0.47)	0.095 (0.0043, 0.47)	1.4 (0.92, 2.1)
1.2 (0.75, 1.7)	1.2 (0.78, 1.6)	1.1 (0.69, 1.6)	ADA+MTX	1 (0.7, 1.4)	0.83 (0.58, 1.1)	0.8 (0.39, 1.6)	0.75 (0.36, 1.5)	0.1 (0.0046, 0.48)	0.1 (0.0046, 0.49)	1.5 (1.2, 1.8)
1.1 (0.75, 1.9)	1.2 (0.9, 1.5)	1.1 (0.67, 1.8)	0.99 (0.73, 1.4)	TCZ+MTX	0.82 (0.54, 1.3)	0.8 (0.38, 1.7)	0.75 (0.36, 1.5)	0.098 (0.0044, 0.48)	0.1 (0.0046, 0.49)	1.5 (1.2, 2)
1.4 (0.87, 2.3)	1.4 (0.88, 2.1)	1.3 (0.9, 1.9)	1.2 (0.87, 1.7)	1.2 (0.78, 1.9)	ABA+MTX	0.97 (0.45, 2.1)	0.9 (0.41, 1.9)	0.12 (0.0053, 0.59)	0.12 (0.0055, 0.6)	1.8 (1.3, 2.6)
1.4 (0.66, 3.1)	1.4 (0.7, 3)	1.3 (0.62, 2.9)	1.2 (0.63, 2.5)	1.2 (0.6, 2.6)	1 (0.48, 2.2)	TOF	0.93 (0.55, 1.6)	0.12 (0.0059, 0.65)	0.12 (0.0056, 0.67)	1.9 (0.95, 3.7)
1.5 (0.73, 3.3)	1.5 (0.75, 3.3)	1.4 (0.67, 3.2)	1.3 (0.67, 2.8)	1.3 (0.66, 2.8)	1.1 (0.52, 2.4)	1.1 (0.63, 1.8)	TOF+MTX	0.13 (0.0057, 0.72)	0.13 (0.0058, 0.74)	2 (1, 3.9)
12 (2.4, 2.5e+02)	12 (2.3, 2.6e+02)	11 (2.1, 2.4e+02)	9.9 (2.1, 2.2e+02)	10 (2.1, 2.3e+02)	8.2 (1.7, 1.9e+02)	8.4 (1.5, 1.7e+02)	7.8 (1.4, 1.7e+02)	IFX+MTX	1 (0.72, 1.5)	15 (3.1, 3.2e+02)
11 (2.3, 2.5e+02)	11 (2.3, 2.5e+02)	11 (2.1, 2.3e+02)	9.8 (2, 2.2e+02)	9.9 (2, 2.2e+02)	8.1 (1.7, 1.8e+02)	8.2 (1.5, 1.8e+02)	7.7 (1.3, 1.7e+02)	0.97 (0.67, 1.4)	MPred+MTX	15 (3.1, 3.2e+02)

CTZ+MTX	TCZ	ABA	ADA+MTX	TCZ+MTX	ABA+MTX	TOF	TOF+MTX	IFX+MTX	MPred+MTX	MTX
0.77 (0.53, 1.1)	0.77 (0.57, 1)	0.72 (0.48, 1.1)	0.67 (0.55, 0.84)	0.67 (0.51, 0.86)	0.55 (0.39, 0.77)	0.54 (0.27, 1.1)	0.5 (0.25, 0.97)	0.066 (0.0031, 0.32)	0.068 (0.0032, 0.32)	MTX

Table 11 ACR50 League Table (Timepoint Sensitivity – 1 yr)

MTX	HCQ+ MTX+SSZ	TCZ	ADA+MTX	ABA	CTZ+MTX	TCZ+MTX	Pred+MTX	ETN+MTX	IFX+MTX	MPred+ MTX	TOF	Pred+SSZ+ MTX	TOF+MTX	ABA+MTX
MTX	0.92 (0.42, 2)	0.85 (0.69, 1.1)	0.85 (0.72, 1)	0.82 (0.62, 1.1)	0.78 (0.64, 0.93)	0.77 (0.63, 0.95)	0.77 (0.54, 1.1)	0.69 (0.53, 0.88)	0.56 (0.32, 0.98)	0.6 (0.28, 1.3)	0.57 (0.43, 0.77)	0.56 (0.27, 1.1)	0.48 (0.31, 0.76)	0.7 (0.54, 0.9)
1.1 (0.5, 2.4)	HCQ+MTX+ SSZ	0.91 (0.4, 2.1)	0.92 (0.4, 2.1)	0.9 (0.4, 2.1)	0.84 (0.39, 1.9)	0.83 (0.38, 1.9)	0.82 (0.36, 2)	0.74 (0.33, 1.7)	0.61 (0.36, 1)	0.64 (0.3, 1.4)	0.62 (0.26, 1.5)	0.59 (0.22, 1.7)	0.52 (0.2, 1.3)	0.75 (0.33, 1.7)
1.2 (0.95, 1.4)	1.1 (0.47, 2.5)	TCZ	0.99 (0.76, 1.3)	0.96 (0.67, 1.4)	0.92 (0.68, 1.2)	0.9 (0.75, 1.1)	0.89 (0.59, 1.3)	0.81 (0.58, 1.1)	0.66 (0.35, 1.2)	0.7 (0.32, 1.5)	0.67 (0.47, 0.97)	0.66 (0.3, 1.4)	0.57 (0.35, 0.91)	0.82 (0.59, 1.1)
1.2 (0.99, 1.4)	1.1 (0.48, 2.5)	1 (0.77, 1.3)	ADA+MTX	0.98 (0.7, 1.4)	0.92 (0.7, 1.2)	0.91 (0.7, 1.2)	0.9 (0.62, 1.3)	0.81 (0.59, 1.1)	0.66 (0.36, 1.2)	0.7 (0.32, 1.6)	0.67 (0.49, 0.95)	0.66 (0.3, 1.3)	0.56 (0.36, 0.92)	0.83 (0.62, 1.1)
1.2 (0.88, 1.6)	1.1 (0.47, 2.5)	1 (0.71, 1.5)	1 (0.73, 1.4)	ABA	0.95 (0.65, 1.3)	0.94 (0.65, 1.3)	0.93 (0.58, 1.4)	0.83 (0.55, 1.2)	0.68 (0.35, 1.3)	0.72 (0.32, 1.6)	0.7 (0.45, 1)	0.67 (0.3, 1.4)	0.58 (0.34, 1)	0.85 (0.63, 1.1)
1.3 (1.1, 1.6)	1.2 (0.52, 2.6)	1.1 (0.83, 1.5)	1.1 (0.85, 1.4)	1.1 (0.75, 1.5)	CTZ+MTX	0.98 (0.76, 1.3)	0.98 (0.66, 1.4)	0.88 (0.65, 1.2)	0.72 (0.39, 1.3)	0.76 (0.35, 1.7)	0.73 (0.52, 1)	0.7 (0.34, 1.5)	0.61 (0.39, 1)	0.9 (0.65, 1.2)
1.3 (1, 1.6)	1.2 (0.52, 2.6)	1.1 (0.91, 1.3)	1.1 (0.85, 1.4)	1.1 (0.74, 1.5)	1 (0.76, 1.3)	TCZ+MTX	0.98 (0.66, 1.5)	0.89 (0.64, 1.2)	0.73 (0.38, 1.3)	0.78 (0.35, 1.7)	0.74 (0.52, 1.1)	0.72 (0.34, 1.5)	0.62 (0.39, 1)	0.9 (0.65, 1.3)
1.3 (0.94, 1.8)	1.2 (0.51, 2.8)	1.1 (0.76, 1.7)	1.1 (0.77, 1.6)	1.1 (0.71, 1.7)	1 (0.7, 1.5)	1 (0.69, 1.5)	Pred+MTX	0.89 (0.59, 1.4)	0.74 (0.38, 1.4)	0.78 (0.35, 1.8)	0.74 (0.49, 1.2)	0.72 (0.38, 1.3)	0.63 (0.37, 1.1)	0.92 (0.6, 1.4)
1.5 (1.1, 1.9)	1.3 (0.58, 3.1)	1.2 (0.9, 1.7)	1.2 (0.92, 1.7)	1.2 (0.82, 1.8)	1.1 (0.83, 1.5)	1.1 (0.82, 1.6)	1.1 (0.73, 1.7)	ETN+MTX	0.82 (0.43, 1.5)	0.87 (0.39, 2.1)	0.83 (0.58, 1.2)	0.82 (0.38, 1.7)	0.69 (0.42, 1.2)	1 (0.71, 1.5)
1.8 (1, 3.2)	1.6 (0.98, 2.5)	1.5 (0.85, 2.5)	1.5 (0.8, 2.8)	1.5 (0.77, 2.5)	1.4 (0.8, 2.6)	1.4 (0.76, 2.5)	1.4 (0.74, 2.5)	1.2 (0.69, 2.5)	IFX+MTX	1.1 (0.61, 2)	1 (0.54, 2.1)	0.99 (0.41, 2.5)	0.86 (0.41, 2.5)	1.2 (0.7, 2.4)

MTX	HCQ+ MTX+SSZ	TCZ	ADA+MTX	ABA	CTZ+MTX	TCZ+MTX	Pred+MTX	ETN+MTX	IFX+MTX	MPred+ MTX	TOF	Pred+SSZ+ MTX	TOF+MTX	ABA+MTX
	2.8)	2.8)		2.9)		2.6)	2.6)	2.3)				2.4)	2)	
1.7 (0.77, 3.6)	1.6 (0.7, 3.3)	1.4 (0.65, 3.2)	1.4 (0.61, 3.1)	1.4 (0.61, 3.1)	1.3 (0.6, 2.9)	1.3 (0.59, 2.9)	1.3 (0.56, 2.9)	1.2 (0.47, 2.5)	0.93 (0.5, 1.6)	MPred+ MTX	0.98 (0.38, 2.2)	0.92 (0.33, 2.6)	0.81 (0.29, 2)	1.2 (0.52, 2.6)
1.7 (1.3, 2.3)	1.6 (0.69, 3.8)	1.5 (1, 2.1)	1.5 (1.1, 2.1)	1.4 (0.95, 2.2)	1.4 (0.96, 1.9)	1.4 (0.93, 1.9)	1.3 (0.85, 2)	1.2 (0.81, 1.7)	0.97 (0.49, 1.9)	1 (0.46, 2.7)	TOF	0.97 (0.43, 2)	0.83 (0.55, 1.3)	1.2 (0.83, 1.8)
1.8 (0.91, 3.8)	1.7 (0.58, 4.6)	1.5 (0.74, 3.3)	1.5 (0.76, 3.3)	1.5 (0.72, 3.4)	1.4 (0.68, 3)	1.4 (0.68, 3)	1.4 (0.76, 2.6)	1.2 (0.6, 2.7)	1 (0.42, 2.4)	1.1 (0.38, 3.1)	1 (0.5, 2.3)	Pred+SSZ+ MTX	0.85 (0.39, 2.1)	1.3 (0.61, 2.8)
2.1 (1.3, 3.2)	1.9 (0.79, 4.9)	1.8 (1.1, 2.8)	1.8 (1.1, 2.8)	1.7 (1, 2.9)	1.6 (1, 2.6)	1.6 (0.98, 2.6)	1.6 (0.92, 2.7)	1.4 (0.84, 2.4)	1.2 (0.5, 2.5)	1.2 (0.51, 3.5)	1.2 (0.79, 1.8)	1.2 (0.48, 2.6)	TOF+MTX	1.5 (0.85, 2.4)
1.4 (1.1, 1.9)	1.3 (0.58, 3)	1.2 (0.88, 1.7)	1.2 (0.94, 1.6)	1.2 (0.9, 1.6)	1.1 (0.81, 1.5)	1.1 (0.8, 1.5)	1.1 (0.72, 1.7)	0.98 (0.68, 1.4)	0.82 (0.42, 1.4)	0.85 (0.39, 1.9)	0.83 (0.56, 1.2)	0.79 (0.36, 1.6)	0.68 (0.41, 1.2)	ABA+MTX

Table 12 ACR50 League Table (Timepoint Sensitivity – 2 yr)

MTX	ETN+MTX	TCZ	TCZ+MTX	TOF	Pred+MTX
MTX	0.64 (0.17, 2.2)	0.61 (0.24, 1.6)	0.62 (0.25, 1.6)	0.61 (0.17, 2.1)	0.8 (0.2, 3)
1.6 (0.44, 5.9)	ETN+MTX	0.95 (0.19, 4.7)	0.96 (0.2, 4.9)	0.94 (0.16, 5.4)	1.2 (0.22, 7.5)
1.6 (0.64, 4.1)	1.1 (0.21, 5.2)	TCZ	1 (0.42, 2.6)	0.99 (0.2, 4.6)	1.3 (0.27, 6.6)
1.6 (0.64, 4)	1 (0.2, 5)	0.99 (0.39, 2.4)	TCZ+MTX	0.96 (0.21, 4.6)	1.3 (0.26, 6.5)
1.7 (0.47, 6)	1.1 (0.18, 6.4)	1 (0.22, 5.1)	1 (0.22, 4.9)	TOF	1.3 (0.2, 8.6)
1.2 (0.33, 4.9)	0.8 (0.13, 4.5)	0.77 (0.15, 3.7)	0.77 (0.15, 3.8)	0.75 (0.12, 5)	Pred+MTX

Table 13 DAS28 Remission League Table (Main Analysis)

MTX	ABA+MTX	CTZ+MTX	ETN+MTX	Pred+MTX	TOF	ADA+MTX	TCZ	TCZ+MTX	TOF+MTX	ABA
MTX	0.73 (0.46, 1.1)	0.63 (0.4, 0.98)	0.61 (0.31, 1.2)	0.63 (0.32, 1.3)	0.62 (0.32, 1.2)	0.59 (0.45, 0.78)	0.58 (0.36, 0.89)	0.54 (0.34, 0.84)	0.42 (0.16, 1.1)	1 (0.57, 1.9)
1.4 (0.87, 2.2)	ABA+MTX	0.87 (0.45, 1.7)	0.83 (0.36, 1.8)	0.87 (0.38, 2)	0.86 (0.38, 1.9)	0.81 (0.51, 1.3)	0.8 (0.41, 1.5)	0.74 (0.39, 1.4)	0.57 (0.2, 1.7)	1.4 (0.77, 2.7)
1.6 (1, 2.5)	1.1 (0.6, 2.2)	CTZ+MTX	0.96 (0.43, 2.1)	0.99 (0.44, 2.3)	0.98 (0.43, 2.1)	0.93 (0.55, 1.6)	0.91 (0.48, 1.7)	0.85 (0.45, 1.6)	0.66 (0.23, 1.9)	1.6 (0.79, 3.6)
1.6 (0.85, 3.2)	1.2 (0.55, 2.8)	1 (0.47, 2.3)	ETN+MTX	1 (0.4, 2.8)	1 (0.4, 2.6)	0.97 (0.48, 2)	0.95 (0.43, 2.1)	0.89 (0.4, 1.9)	0.69 (0.22, 2.3)	1.7 (0.71, 4.3)
1.6 (0.79, 3.1)	1.1 (0.49, 2.6)	1 (0.44, 2.3)	0.96 (0.35, 2.5)	Pred+MTX	0.98 (0.37, 2.5)	0.94 (0.43, 1.9)	0.92 (0.39, 2)	0.85 (0.35, 2)	0.66 (0.2, 2.2)	1.7 (0.65, 4.2)
1.6 (0.85, 3.1)	1.2 (0.53, 2.7)	1 (0.47, 2.3)	0.98 (0.39, 2.5)	1 (0.4, 2.7)	TOF	0.95 (0.46, 2)	0.94 (0.42, 2.1)	0.87 (0.39, 1.9)	0.68 (0.27, 1.7)	1.7 (0.69, 4.3)
1.7 (1.3, 2.2)	1.2 (0.76, 2)	1.1 (0.63, 1.8)	1 (0.5, 2.1)	1.1 (0.52, 2.3)	1.1 (0.5, 2.2)	ADA+MTX	0.99 (0.57, 1.6)	0.92 (0.53, 1.5)	0.71 (0.27, 2)	1.8 (0.93, 3.4)
1.7 (1.1, 2.7)	1.2 (0.66, 2.4)	1.1 (0.58, 2.1)	1.1 (0.48, 2.3)	1.1 (0.49, 2.6)	1.1 (0.48, 2.4)	1 (0.63, 1.7)	TCZ	0.93 (0.61, 1.4)	0.73 (0.26, 2.2)	1.8 (0.85, 4)
1.9 (1.2, 3)	1.3 (0.7, 2.6)	1.2 (0.63, 2.2)	1.1 (0.51, 2.5)	1.2 (0.51, 2.8)	1.1 (0.53, 2.6)	1.1 (0.65, 1.9)	1.1 (0.69, 1.6)	TCZ+MTX	0.78 (0.28, 2.3)	1.9 (0.93, 4.3)
2.4 (0.89, 6.1)	1.7 (0.59, 5)	1.5 (0.51, 4.3)	1.4 (0.44, 4.6)	1.5 (0.46, 4.9)	1.5 (0.59, 3.6)	1.4 (0.5, 3.7)	1.4 (0.46, 3.9)	1.3 (0.44, 3.6)	TOF+MTX	2.5 (0.78, 7.6)
0.96 (0.52, 1.7)	0.69 (0.37, 1.3)	0.61 (0.28, 1.3)	0.58 (0.23, 1.4)	0.6 (0.24, 1.5)	0.6 (0.23, 1.4)	0.57 (0.29, 1.1)	0.55 (0.25, 1.2)	0.52 (0.23, 1.1)	0.4 (0.13, 1.3)	ABA

Table 14 DAS28 Remission League Table (Timepoint Sensitivity – 6 mo)

TOF	MTX	ETN+MTX	CTZ+MTX	ADA+MTX	TOF+MTX	ABA+MTX	TCZ	TCZ+MTX	ABA
TOF	0.91 (0.24, 2.8)	0.51 (0.13, 1.7)	0.52 (0.13, 1.8)	0.48 (0.13, 1.5)	0.47 (0.15, 1.2)	0.43 (0.11, 1.5)	0.42 (0.11, 1.4)	0.38 (0.1, 1.3)	0.62 (0.14, 2.2)
1.1 (0.35, 4.2)	MTX	0.56 (0.37, 0.85)	0.57 (0.38, 0.87)	0.53 (0.42, 0.68)	0.54 (0.18, 1.4)	0.47 (0.31, 0.69)	0.46 (0.34, 0.62)	0.42 (0.31, 0.55)	0.68 (0.42, 1.1)
2 (0.58, 7.5)	1.8 (1.2, 2.7)	ETN+MTX	1 (0.57, 1.9)	0.94 (0.57, 1.5)	0.96 (0.28, 2.7)	0.84 (0.47, 1.5)	0.82 (0.48, 1.4)	0.74 (0.44, 1.2)	1.2 (0.65, 2.3)
1.9 (0.57, 7.7)	1.7 (1.2, 2.6)	0.99 (0.54, 1.8)	CTZ+MTX	0.92 (0.58, 1.5)	0.93 (0.29, 2.6)	0.83 (0.47, 1.5)	0.81 (0.49, 1.3)	0.73 (0.45, 1.2)	1.2 (0.65, 2.3)
2.1 (0.65, 7.8)	1.9 (1.5, 2.4)	1.1 (0.65, 1.7)	1.1 (0.69, 1.7)	ADA+MTX	1 (0.33, 2.7)	0.9 (0.59, 1.3)	0.88 (0.6, 1.3)	0.8 (0.55, 1.1)	1.3 (0.79, 2.1)
2.1 (0.81, 6.9)	1.9 (0.72, 5.5)	1 (0.37, 3.5)	1.1 (0.38, 3.5)	0.99 (0.38, 3.1)	TOF+MTX	0.89 (0.32, 2.9)	0.87 (0.32, 2.7)	0.78 (0.29, 2.5)	1.3 (0.46, 4.4)
2.3 (0.67, 9.3)	2.1 (1.4, 3.2)	1.2 (0.67, 2.1)	1.2 (0.68, 2.1)	1.1 (0.75, 1.7)	1.1 (0.35, 3.1)	ABA+MTX	0.97 (0.6, 1.6)	0.88 (0.53, 1.5)	1.4 (0.95, 2.2)
2.4 (0.73, 9.3)	2.2 (1.6, 2.9)	1.2 (0.72, 2.1)	1.2 (0.75, 2)	1.1 (0.79, 1.7)	1.2 (0.36, 3.1)	1 (0.63, 1.7)	TCZ	0.91 (0.7, 1.2)	1.5 (0.84, 2.6)
2.6 (0.8, 10)	2.4 (1.8, 3.2)	1.3 (0.8, 2.3)	1.4 (0.84, 2.2)	1.2 (0.89, 1.8)	1.3 (0.39, 3.4)	1.1 (0.69, 1.9)	1.1 (0.86, 1.4)	TCZ+MTX	1.6 (0.93, 2.9)
1.6 (0.45, 7)	1.5 (0.9, 2.4)	0.83 (0.43, 1.5)	0.84 (0.44, 1.5)	0.77 (0.47, 1.3)	0.78 (0.23, 2.2)	0.69 (0.46, 1.1)	0.68 (0.39, 1.2)	0.61 (0.35, 1.1)	ABA

Table 15 DAS28 Remission League Table (Timepoint Sensitivity – 1 yr)

MTX	ABA	ADA+MTX	TCZ	CTZ+MTX	TCZ+MTX	ETN+MTX	TOF	TOF+MTX	ABA+MTX
MTX	0.96 (0.44, 2)	0.77 (0.47, 1.3)	0.63 (0.35, 1.1)	0.63 (0.34, 1.1)	0.6 (0.34, 1.1)	0.55 (0.25, 1.3)	0.52 (0.24, 1.1)	0.34 (0.12, 0.97)	0.62 (0.32, 1.1)
1 (0.49, 2.3)	ABA	0.8 (0.34, 1.9)	0.66 (0.25, 1.7)	0.66 (0.24, 1.7)	0.63 (0.24, 1.6)	0.58 (0.19, 1.8)	0.54 (0.19, 1.7)	0.36 (0.099, 1.3)	0.65 (0.29, 1.4)
1.3 (0.78, 2.1)	1.2 (0.54, 2.9)	ADA+MTX	0.82 (0.38, 1.8)	0.83 (0.37, 1.7)	0.78 (0.37, 1.7)	0.73 (0.28, 1.9)	0.67 (0.27, 1.7)	0.44 (0.15, 1.4)	0.81 (0.4, 1.5)
1.6 (0.89, 2.8)	1.5 (0.59, 4)	1.2 (0.57, 2.6)	TCZ	1 (0.42, 2.3)	0.96 (0.53, 1.6)	0.89 (0.32, 2.4)	0.82 (0.33, 2.2)	0.54 (0.17, 1.8)	0.99 (0.41, 2.3)
1.6 (0.92, 2.9)	1.5 (0.6, 4.1)	1.2 (0.58, 2.7)	1 (0.44, 2.4)	CTZ+MTX	0.95 (0.42, 2.2)	0.88 (0.35, 2.3)	0.81 (0.34, 2.2)	0.54 (0.17, 1.8)	0.99 (0.42, 2.3)
1.7 (0.94, 3)	1.6 (0.62, 4.1)	1.3 (0.6, 2.7)	1 (0.61, 1.9)	1.1 (0.45, 2.4)	TCZ+MTX	0.93 (0.34, 2.6)	0.86 (0.35, 2.3)	0.57 (0.18, 1.9)	1 (0.44, 2.3)
1.8 (0.79, 4)	1.7 (0.57, 5.3)	1.4 (0.52, 3.6)	1.1 (0.41, 3.1)	1.1 (0.43, 2.9)	1.1 (0.39, 3)	ETN+MTX	0.93 (0.31, 2.8)	0.61 (0.17, 2.3)	1.1 (0.37, 2.9)
1.9 (0.9, 4.2)	1.9 (0.6, 5.3)	1.5 (0.58, 3.6)	1.2 (0.46, 3.1)	1.2 (0.45, 3)	1.2 (0.43, 2.9)	1.1 (0.36, 3.3)	TOF	0.67 (0.24, 1.7)	1.2 (0.42, 3.1)
2.9 (1, 8)	2.8 (0.76, 10)	2.3 (0.72, 6.8)	1.8 (0.55, 5.8)	1.9 (0.56, 5.8)	1.8 (0.53, 5.5)	1.6 (0.43, 6)	1.5 (0.58, 4.2)	TOF+MTX	1.8 (0.55, 5.8)
1.6 (0.89, 3.1)	1.5 (0.73, 3.4)	1.2 (0.65, 2.5)	1 (0.44, 2.4)	1 (0.44, 2.4)	0.97 (0.43, 2.3)	0.9 (0.34, 2.7)	0.83 (0.33, 2.4)	0.56 (0.17, 1.8)	ABA+MTX

Table 16 DAS28 Remission League Table (Timepoint Sensitivity – 2 yr)

MTX	ETN+MTX	TCZ	TOF	TCZ+MTX
MTX	0.6 (0.15, 2.4)	0.56 (0.22, 1.5)	0.55 (0.13, 2.2)	0.52 (0.21, 1.4)
1.7 (0.42, 6.7)	ETN+MTX	0.94 (0.19, 5.1)	0.89 (0.13, 7.1)	0.87 (0.17, 5.1)
1.8 (0.69, 4.6)	1.1 (0.2, 5.3)	TCZ	0.97 (0.17, 5.2)	0.94 (0.36, 2.3)
1.8 (0.45, 7.8)	1.1 (0.14, 7.8)	1 (0.19, 5.8)	TOF	0.97 (0.18, 5.5)
1.9 (0.72, 4.8)	1.2 (0.2, 5.8)	1.1 (0.43, 2.8)	1 (0.18, 5.7)	TCZ+MTX

Table 17 All-Cause Withdrawal League Table (Main Analysis)

TOF+ MTX	Pred	TOF	Pred+ SSZ+ MTX	MPred+ MTX	ETN+ MTX	CTZ+ MTX	ADA+ MTX	TCZ	ETN	TCZ+ MTX	MTX	SSZ+ MTX	Pred+ MTX	SSZ	ABA	HCQ+ Pred+ SSZ+ MTX	IFX+ MTX	HCQ+ SSZ+ MTX	ABA+ MTX
TOF+ MTX	0.97 (0.3, 3.1)	0.87 (0.36, 2.2)	0.82 (0.15, 5.4)	0.76 (0.055, 22)	0.72 (0.28, 1.8)	0.67 (0.29, 1.6)	0.58 (0.25, 1.3)	0.58 (0.23, 1.4)	0.57 (0.0085, 19)	0.49 (0.2, 1.2)	0.48 (0.21, 1)	0.48 (0.19, 1.2)	0.49 (0.18, 1.3)	0.41 (0.15, 1.1)	0.38 (0.14, 1)	0.25 (0.063, 1)	0.25 (0.02, 1.6)	0.17 (0.014, 1.2)	0.67 (0.25, 1.7)
1 (0.32, 3.4)	Pred	0.9 (0.28, 2.9)	0.84 (0.15, 5.8)	0.79 (0.055, 22)	0.73 (0.27, 2)	0.68 (0.28, 1.8)	0.6 (0.25, 1.5)	0.59 (0.23, 1.6)	0.59 (0.0089, 21)	0.5 (0.2, 1.3)	0.49 (0.21, 1.2)	0.49 (0.21, 1.2)	0.51 (0.19, 1.4)	0.42 (0.23, 0.74)	0.39 (0.13, 1.1)	0.26 (0.083, 0.81)	0.25 (0.021, 1.7)	0.17 (0.013, 1.2)	0.69 (0.25, 1.8)
1.1 (0.46, 2.8)	1.1 (0.34, 3.6)	TOF	0.91 (0.18, 6.1)	0.9 (0.057, 27)	0.82 (0.33, 2)	0.77 (0.34, 1.8)	0.68 (0.29, 1.5)	0.66 (0.28, 1.5)	0.64 (0.01, 20)	0.57 (0.23, 1.3)	0.55 (0.25, 1.1)	0.55 (0.2, 1.4)	0.56 (0.21, 1.5)	0.47 (0.17, 1.3)	0.44 (0.16, 1.1)	0.3 (0.072, 1.2)	0.27 (0.025, 1.8)	0.19 (0.013, 1.4)	0.76 (0.3, 1.9)
1.2 (0.18, 6.7)	1.2 (0.17, 6.6)	1.1 (0.16, 5.5)	Pred+ SSZ+MTX	0.98 (0.056, 29)	0.89 (0.15, 4.3)	0.84 (0.15, 3.8)	0.73 (0.12, 3.2)	0.73 (0.12, 3.3)	0.63 (0.014, 25)	0.61 (0.1, 2.7)	0.6 (0.11, 2.5)	0.6 (0.095, 2.9)	0.62 (0.13, 2.4)	0.5 (0.082, 2.5)	0.48 (0.077, 2.4)	0.31 (0.039, 2.2)	0.29 (0.022, 2.5)	0.2 (0.014, 1.9)	0.83 (0.14, 4)
1.3 (0.046, 18)	1.3 (0.045, 18)	1.1 (0.037, 17)	1 (0.034, 18)	MPred+ MTX	0.95 (0.033, 12)	0.88 (0.034, 11)	0.77 (0.028, 9.6)	0.76 (0.027, 8.8)	0.59 (0.0056, 59)	0.65 (0.024, 7.9)	0.63 (0.024, 7.4)	0.63 (0.022, 7.7)	0.63 (0.025, 8.8)	0.53 (0.019, 7.5)	0.47 (0.018, 6.9)	0.33 (0.0093, 6.3)	0.29 (0.017, 2.4)	0.2 (0.011, 1.7)	0.84 (0.032, 11)

TOF+ MTX	Pred	TOF	Pred+ SSZ+ MTX	MPred+ MTX	ETN+ MTX	CTZ+ MTX	ADA+ MTX	TCZ	ETN	TCZ+ MTX	MTX	SSZ+ MTX	Pred+ MTX	SSZ	ABA	HCQ+ Pred+ SSZ+ MTX	IFX+ MTX	HCQ+ SSZ+ MTX	ABA+ MTX
1.4 (0.56, 3.6)	1.4 (0.49, 3.7)	1.2 (0.5, 3)	1.1 (0.23, 6.7)	1.1 (0.084, 30)	ETN+ MTX	0.94 (0.53, 1.8)	0.83 (0.45, 1.5)	0.81 (0.42, 1.5)	0.8 (0.015, 25)	0.7 (0.35, 1.3)	0.67 (0.39, 1.1)	0.67 (0.31, 1.4)	0.7 (0.31, 1.5)	0.57 (0.25, 1.3)	0.53 (0.24, 1.2)	0.35 (0.096, 1.3)	0.34 (0.037, 1.9)	0.23 (0.02, 1.4)	0.92 (0.45, 1.9)
1.5 (0.64, 3.4)	1.5 (0.56, 3.6)	1.3 (0.56, 3)	1.2 (0.27, 6.8)	1.1 (0.088, 30)	1.1 (0.55, 1.9)	CTZ+ MTX	0.88 (0.55, 1.3)	0.86 (0.51, 1.4)	0.85 (0.016, 25)	0.74 (0.43, 1.2)	0.72 (0.49, 0.94)	0.72 (0.37, 1.3)	0.73 (0.38, 1.4)	0.61 (0.3, 1.2)	0.56 (0.27, 1.1)	0.38 (0.11, 1.3)	0.36 (0.037, 2)	0.24 (0.022, 1.4)	0.98 (0.53, 1.8)
1.7 (0.75, 4)	1.7 (0.67, 4)	1.5 (0.66, 3.4)	1.4 (0.31, 8.2)	1.3 (0.1, 36)	1.2 (0.69, 2.2)	1.1 (0.78, 1.8)	ADA+ MTX	0.98 (0.62, 1.6)	0.97 (0.018, 29)	0.84 (0.51, 1.3)	0.81 (0.59, 1.1)	0.82 (0.44, 1.6)	0.84 (0.45, 1.6)	0.7 (0.34, 1.4)	0.64 (0.34, 1.2)	0.44 (0.13, 1.5)	0.4 (0.046, 2.2)	0.28 (0.027, 1.6)	1.1 (0.69, 1.9)
1.7 (0.72, 4.3)	1.7 (0.64, 4.3)	1.5 (0.65, 3.6)	1.4 (0.31, 8.3)	1.3 (0.11, 36)	1.2 (0.66, 2.4)	1.2 (0.73, 2)	1 (0.63, 1.6)	TCZ	0.96 (0.02, 30)	0.85 (0.56, 1.2)	0.82 (0.56, 1.2)	0.84 (0.41, 1.6)	0.84 (0.44, 1.8)	0.71 (0.34, 1.5)	0.65 (0.32, 1.4)	0.44 (0.13, 1.5)	0.41 (0.044, 2.3)	0.28 (0.027, 1.6)	1.1 (0.61, 2.2)
1.7 (0.054, 1.2e+02)	1.7 (0.049, 1.1e+02)	1.6 (0.049, 1e+02)	1.6 (0.04, 73)	1.7 (0.017, 1.8e+02)	1.2 (0.04, 66)	1.2 (0.039, 61)	1 (0.035, 55)	1 (0.033, 49)	ETN	0.85 (0.027, 42)	0.82 (0.028, 43)	0.84 (0.027, 43)	0.85 (0.026, 46)	0.7 (0.022, 46)	0.67 (0.022, 43)	0.45 (0.012, 27)	0.44 (0.0055, 28)	0.29 (0.0033, 22)	1.2 (0.039, 60)
2 (0.86, 4.9)	2 (0.78, 5.1)	1.8 (0.77, 4.3)	1.6 (0.37, 9.9)	1.5 (0.13, 42)	1.4 (0.78, 2.9)	1.4 (0.86, 2.3)	1.2 (0.76, 1.9)	1.2 (0.81, 1.8)	1.2 (0.024, 37)	TCZ+ MTX	0.97 (0.67, 1.4)	0.98 (0.49, 2)	1 (0.52, 2)	0.84 (0.4, 1.8)	0.76 (0.38, 1.6)	0.52 (0.15, 1.8)	0.49 (0.053, 2.7)	0.33 (0.032, 2)	1.3 (0.72, 2.6)

TOF+ MTX	Pred	TOF	Pred+ SSZ+ MTX	MPred+ MTX	ETN+ MTX	CTZ+ MTX	ADA+ MTX	TCZ	ETN	TCZ+ MTX	MTX	SSZ+ MTX	Pred+ MTX	SSZ	ABA	HCQ+ Pred+ SSZ+ MTX	IFX+ MTX	HCQ+ SSZ+ MTX	ABA+ MTX
2.1 (0.97, 4.8)	2.1 (0.86, 4.8)	1.8 (0.87, 4)	1.7 (0.4, 9.4)	1.6 (0.13, 42)	1.5 (0.9, 2.6)	1.4 (1.1, 2)	1.2 (0.92, 1.7)	1.2 (0.83, 1.8)	1.2 (0.023, 36)	1 (0.7, 1.5)	MTX	1 (0.57, 1.8)	1 (0.59, 1.8)	0.86 (0.47, 1.6)	0.79 (0.43, 1.5)	0.53 (0.17, 1.7)	0.5 (0.056, 2.8)	0.34 (0.034, 2)	1.4 (0.84, 2.3)
2.1 (0.81, 5.4)	2 (0.82, 4.8)	1.8 (0.71, 4.9)	1.7 (0.35, 10)	1.6 (0.13, 46)	1.5 (0.69, 3.2)	1.4 (0.76, 2.7)	1.2 (0.64, 2.3)	1.2 (0.62, 2.5)	1.2 (0.023, 38)	1 (0.5, 2)	0.99 (0.56, 1.7)	SSZ+ MTX	1 (0.46, 2.2)	0.86 (0.44, 1.6)	0.79 (0.35, 1.8)	0.54 (0.16, 1.7)	0.5 (0.049, 3)	0.34 (0.031, 2.2)	1.4 (0.65, 3)
2 (0.76, 5.4)	2 (0.71, 5.4)	1.8 (0.67, 4.7)	1.6 (0.43, 8)	1.6 (0.11, 40)	1.4 (0.68, 3.2)	1.4 (0.73, 2.6)	1.2 (0.63, 2.2)	1.2 (0.57, 2.3)	1.2 (0.022, 38)	1 (0.5, 1.9)	0.97 (0.55, 1.7)	0.96 (0.45, 2.2)	Pred+ MTX	0.82 (0.36, 2)	0.77 (0.33, 1.8)	0.51 (0.14, 1.9)	0.5 (0.049, 2.8)	0.33 (0.029, 2.1)	1.4 (0.63, 2.9)
2.4 (0.91, 6.7)	2.4 (1.4, 4.3)	2.1 (0.78, 5.9)	2 (0.4, 12)	1.9 (0.13, 54)	1.8 (0.77, 3.9)	1.6 (0.82, 3.4)	1.4 (0.72, 2.9)	1.4 (0.68, 2.9)	1.4 (0.022, 45)	1.2 (0.56, 2.5)	1.2 (0.61, 2.1)	1.2 (0.64, 2.2)	1.2 (0.5, 2.8)	SSZ	0.94 (0.39, 2.2)	0.63 (0.23, 1.6)	0.6 (0.058, 3.7)	0.41 (0.036, 2.7)	1.6 (0.68, 3.6)
2.6 (0.99, 7.1)	2.6 (0.91, 7.5)	2.3 (0.87, 6.3)	2.1 (0.42, 13)	2.1 (0.14, 57)	1.9 (0.86, 4.2)	1.8 (0.91, 3.6)	1.6 (0.81, 2.9)	1.5 (0.72, 3.1)	1.5 (0.023, 46)	1.3 (0.62, 2.6)	1.3 (0.67, 2.3)	1.3 (0.56, 2.9)	1.3 (0.56, 3)	1.1 (0.45, 2.6)	ABA	0.66 (0.17, 2.6)	0.64 (0.064, 3.9)	0.44 (0.042, 3)	1.7 (0.9, 3.4)
3.9 (0.96, 16)	3.8 (1.2, 12)	3.4 (0.81, 14)	3.2 (0.46, 25)	3 (0.16, 1.1e+02)	2.9 (0.75, 10)	2.6 (0.77, 8.8)	2.3 (0.68, 7.7)	2.3 (0.66, 7.6)	2.2 (0.037, 80)	1.9 (0.55, 6.6)	1.9 (0.58, 6)	1.8 (0.61, 6.3)	2 (0.54, 7.2)	1.6 (0.61, 4.4)	1.5 (0.39, 5.9)	HCQ+ Pred+ SSZ+	0.94 (0.06, 7.8)	0.64 (0.04, 5.6)	2.6 (0.72, 9.3)

TOF+ MTX	Pred	TOF	Pred+ SSZ+ MTX	MPred+ MTX	ETN+ MTX	CTZ+ MTX	ADA+ MTX	TCZ	ETN	TCZ+ MTX	MTX	SSZ+ MTX	Pred+ MTX	SSZ	ABA	HCQ+ Pred+ SSZ+ MTX	IFX+ MTX	HCQ+ SSZ+ MTX	ABA+ MTX
																MTX			
4 (0.62, 49)	4 (0.6, 49)	3.7 (0.57, 40)	3.4 (0.4, 45)	3.4 (0.43, 58)	2.9 (0.52, 27)	2.8 (0.5, 27)	2.5 (0.45, 22)	2.4 (0.44, 23)	2.3 (0.035, 1.8e+02)	2 (0.38, 19)	2 (0.36, 18)	2 (0.33, 20)	2 (0.36, 20)	1.7 (0.27, 17)	1.6 (0.26, 16)	1.1 (0.13, 17)	IFX+ MTX	0.68 (0.4, 1.1)	2.7 (0.47, 25)
5.9 (0.86, 74)	5.8 (0.82, 76)	5.4 (0.74, 74)	5 (0.53, 69)	5 (0.58, 90)	4.4 (0.71, 49)	4.1 (0.69, 46)	3.6 (0.62, 37)	3.6 (0.61, 37)	3.4 (0.046, 3e+02)	3 (0.5, 32)	2.9 (0.51, 29)	2.9 (0.46, 32)	3 (0.49, 34)	2.4 (0.37, 27)	2.3 (0.34, 24)	1.6 (0.18, 25)	1.5 (0.88, 2.5)	HCQ+ SSZ+ MTX	4 (0.63, 42)
1.5 (0.59, 4.1)	1.5 (0.55, 4.1)	1.3 (0.54, 3.3)	1.2 (0.25, 7.4)	1.2 (0.09, 31)	1.1 (0.53, 2.2)	1 (0.57, 1.9)	0.89 (0.53, 1.5)	0.88 (0.46, 1.6)	0.86 (0.017, 25)	0.75 (0.39, 1.4)	0.72 (0.43, 1.2)	0.73 (0.33, 1.5)	0.74 (0.35, 1.6)	0.61 (0.28, 1.5)	0.58 (0.3, 1.1)	0.38 (0.11, 1.4)	0.38 (0.04, 2.1)	0.25 (0.024, 1.6)	ABA+ MTX

Table 18 Adverse Event Withdrawal (Main Analysis)

MPred +MTX	Pred	TOF	ABA+ MTX	Pred MTX	TOF+ MTX	Pred+ SSZ+ MTX	ETN+ MTX	MTX	CTZ+ MTX	TCZ	ADA+ MTX	Mpred +Pred+ MTX	SSZ	SSZ+ MTX	TCZ+ MTX	Lefl	IFX+ MTX	HCQ+ Pred+ SSZ+ MTX	HCQ+ SSZ+ MTX	ABA
MPred+ MTX	0.00062 (1.3e-22, 1.2e+07)	0.00051 (1.2e-22, 1.3e+07)	0.00042 (1.3e-22, 9.5e+06)	0.00045 (1.3e-22, 9.9e+06)	0.00041 (1.1e-22, 7.6e+06)	0.00041 (2.6e-22, 1e+07)	0.00045 (1.2e-22, 9.4e+06)	0.00037 (7.5e-23, 8.5e+06)	0.00034 (7.2e-23, 7.2e+06)	0.00025 (4.2e-23, 5.4e+06)	0.00025 (5e-23, 5.6e+06)	0.00011 (3.3e-23, 1.2e+07)	0.00021 (4.3e-23, 4.1e+06)	0.00023 (4.6e-23, 4.6e+06)	0.00017 (3.2e-23, 3.7e+06)	2.9e-05 (6e-24, 9e+05)	3e-15 (1.4e-29, 0.22)	1.7e-12 (9e-29, 0.19)	2.7e-15 (1.3e-29, 0.15)	0.00024 (4.9e-23, 4.1e+06)
1.6e+03 (8.4e-08, 7.5e+21)	Pred	0.84 (0.17, 4.8)	0.76 (0.14, 4.6)	0.73 (0.15, 4.2)	0.67 (0.096, 5.4)	0.71 (0.044, 12)	0.66 (0.11, 3.6)	0.53 (0.12, 2.3)	0.5 (0.1, 2.4)	0.39 (0.079, 1.9)	0.37 (0.083, 1.8)	0.38 (0.0067, 42)	0.35 (0.15, 0.87)	0.35 (0.089, 1.5)	0.27 (0.056, 1.3)	0.061 (0.0019, 0.66)	7.9e-08 (1.4e-27, 0.017)	6e-08 (5e-21, 1.3)	6.3e-08 (1.1e-27, 0.014)	0.33 (0.055, 2.3)
2e+03 (7.8e-08, 8.4e+21)	1.2 (0.21, 6)	TOF	0.92 (0.24, 3.3)	0.88 (0.27, 2.9)	0.79 (0.2, 3.6)	0.85 (0.069, 9.5)	0.78 (0.23, 2.3)	0.63 (0.26, 1.3)	0.61 (0.19, 1.5)	0.46 (0.15, 1.3)	0.45 (0.16, 1.1)	0.42 (0.0072, 60)	0.43 (0.097, 1.6)	0.41 (0.12, 1.4)	0.31 (0.11, 0.86)	0.072 (0.0025, 0.57)	9.6e-08 (1.1e-27, 0.02)	7.4e-08 (6.2e-21, 1.6)	7.9e-08 (9.6e-28, 0.015)	0.41 (0.09, 1.5)
2.4e+03 (1.1e-07, 7.7e+21)	1.3 (0.22, 7.2)	1.1 (0.3, 4.2)	ABA+ MTX	0.94 (0.26, 3.7)	0.87 (0.15, 4.7)	0.87 (0.077, 12)	0.86 (0.23, 3.1)	0.7 (0.23, 1.9)	0.65 (0.19, 2.1)	0.5 (0.15, 1.7)	0.48 (0.16, 1.3)	0.47 (0.0093, 54)	0.46 (0.1, 2)	0.44 (0.11, 1.8)	0.34 (0.1, 1.2)	0.078 (0.0028, 0.69)	1.1e-07 (1.3e-27, 0.018)	9.1e-08 (7.9e-21, 1.8)	9e-08 (1e-27, 0.015)	0.43 (0.14, 1.5)
2.2e+03 (1e-07, 7.5e+21)	1.4 (0.24, 6.8)	1.1 (0.35, 3.7)	1.1 (0.27, 3.9)	Pred+ MTX	0.91 (0.18, 4.6)	0.97 (0.1, 8.8)	0.92 (0.25, 2.8)	0.74 (0.29, 1.6)	0.7 (0.21, 1.9)	0.52 (0.16, 1.5)	0.52 (0.18, 1.3)	0.49 (0.01, 60)	0.49 (0.12, 1.9)	0.47 (0.14, 1.7)	0.37 (0.11, 1.1)	0.084 (0.0028, 0.61)	1.1e-07 (1.5e-27, 0.021)	8.8e-08 (7.1e-21, 1.4)	9.5e-08 (1.1e-27, 0.018)	0.46 (0.095, 1.8)

MPred +MTX	Pred	TOF	ABA+ MTX	Pred MTX	TOF+ MTX	Pred+ SSZ+ MTX	ETN+ MTX	MTX	CTZ+ MTX	TCZ	ADA+ MTX	Mpred +Pred+ MTX	SSZ	SSZ+ MTX	TCZ+ MTX	Lefl	IFX+ MTX	HCQ+ Pred+ SSZ+ MTX	HCQ+ SSZ+ MTX	ABA
2.4e+03 (1.3e-07, 9.4e+21)	1.5 (0.19, 10)	1.3 (0.27, 5.1)	1.2 (0.21, 6.8)	1.1 (0.22, 5.6)	TOF+ MTX	1 (0.068, 17)	0.97 (0.18, 4.6)	0.79 (0.18, 3)	0.75 (0.15, 3.2)	0.56 (0.11, 2.7)	0.55 (0.12, 2.4)	0.56 (0.0097, 71)	0.53 (0.082, 3.1)	0.52 (0.091, 2.6)	0.39 (0.081, 1.8)	0.089 (0.0026, 0.98)	1.3e-07 (1.5e-27, 0.023)	8.7e-08 (1.3e-20, 2.1)	1.2e-07 (1.2e-27, 0.02)	0.48 (0.08, 3.2)
2.4e+03 (9.8e-08, 3.9e+21)	1.4 (0.086, 23)	1.2 (0.1, 15)	1.1 (0.083, 13)	1 (0.11, 9.7)	0.97 (0.058, 15)	Pred+ SSZ+ MTX	0.97 (0.078, 12)	0.78 (0.07, 7.7)	0.74 (0.055, 7.6)	0.57 (0.046, 6.5)	0.54 (0.047, 6.2)	0.54 (0.0078, 72)	0.5 (0.035, 6.9)	0.48 (0.04, 6.5)	0.39 (0.033, 4.4)	0.079 (0.002, 1.5)	9.8e-08 (1.6e-27, 0.026)	5.1e-08 (6.4e-21, 2.7)	8.6e-08 (1.1e-27, 0.024)	0.48 (0.033, 7.4)
2.2e+03 (1.1e-07, 8.7e+21)	1.5 (0.28, 8.9)	1.3 (0.44, 4.4)	1.2 (0.33, 4.4)	1.1 (0.36, 4)	1 (0.22, 5.5)	1 (0.081, 13)	ETN+ MTX	0.81 (0.34, 1.9)	0.77 (0.24, 2.1)	0.59 (0.19, 1.7)	0.58 (0.21, 1.6)	0.57 (0.011, 65)	0.54 (0.13, 2.3)	0.54 (0.15, 1.9)	0.4 (0.15, 1.3)	0.097 (0.0034, 0.72)	1.3e-07 (1.8e-27, 0.024)	1.1e-07 (8.3e-21, 2)	1e-07 (1.4e-27, 0.019)	0.52 (0.12, 2.1)
2.7e+03 (1.2e-07, 1.3e+22)	1.9 (0.44, 8.1)	1.6 (0.76, 3.9)	1.4 (0.54, 4.3)	1.4 (0.62, 3.4)	1.3 (0.33, 5.4)	1.3 (0.13, 14)	1.2 (0.52, 2.9)	MTX	0.96 (0.46, 1.8)	0.72 (0.37, 1.4)	0.71 (0.41, 1.2)	0.7 (0.014, 78)	0.66 (0.22, 2.2)	0.65 (0.27, 1.8)	0.49 (0.26, 1)	0.12 (0.0041, 0.79)	1.6e-07 (2e-27, 0.028)	1.3e-07 (9e-21, 2.3)	1.3e-07 (1.6e-27, 0.023)	0.63 (0.18, 2)
3e+03 (1.4e-07, 1.4e+22)	2 (0.42, 9.8)	1.7 (0.65, 5.3)	1.5 (0.47, 5.2)	1.4 (0.52, 4.8)	1.3 (0.31, 6.7)	1.3 (0.13, 18)	1.3 (0.47, 4.1)	1 (0.56, 2.2)	CTZ+ MTX	0.75 (0.31, 2.2)	0.74 (0.33, 1.9)	0.75 (0.014, 82)	0.71 (0.2, 2.7)	0.7 (0.23, 2.3)	0.52 (0.22, 1.5)	0.12 (0.0044, 0.91)	1.7e-07 (1.9e-27, 0.03)	1.3e-07 (9.2e-21, 2.5)	1.3e-07 (1.4e-27, 0.025)	0.67 (0.17, 2.8)
3.9e+03 (1.9e-07, 2.4e+22)	2.5 (0.52, 13)	2.2 (0.79, 6.8)	2 (0.6, 6.8)	1.9 (0.65, 6.3)	1.8 (0.37, 9)	1.8 (0.15, 22)	1.7 (0.57, 5.3)	1.4 (0.7, 2.7)	1.3 (0.46, 3.2)	TCZ	1 (0.4, 2.4)	0.99 (0.017, 1.2e+02)	0.91 (0.24, 3.2)	0.91 (0.28, 2.9)	0.68 (0.36, 1.4)	0.17 (0.0053, 1.2)	2.2e-07 (3e-27, 0.041)	2e-07 (1.3e-20, 3.2)	1.9e-07 (2.5e-27, 0.034)	0.88 (0.21, 3.4)

MPred +MTX	Pred	TOF	ABA+ MTX	Pred MTX	TOF+ MTX	Pred+ SSZ+ MTX	ETN+ MTX	MTX	CTZ+ MTX	TCZ	ADA+ MTX	Mpred +Pred+ MTX	SSZ	SSZ+ MTX	TCZ+ MTX	Lefl	IFX+ MTX	HCQ+ Pred+ SSZ+ MTX	HCQ+ SSZ+ MTX	ABA
3.9e+03 (1.8e-07, 2e+22)	2.7 (0.57, 12)	2.2 (0.89, 6.1)	2.1 (0.75, 6.2)	1.9 (0.74, 5.7)	1.8 (0.42, 8.5)	1.9 (0.16, 21)	1.7 (0.63, 4.8)	1.4 (0.81, 2.5)	1.3 (0.53, 3)	1 (0.42, 2.5)	ADA+ MTX	0.96 (0.02, 1.1e+02)	0.95 (0.27, 3.2)	0.91 (0.34, 2.9)	0.69 (0.3, 1.8)	0.16 (0.0058, 1.2)	2.3e-07 (2.5e-27, 0.036)	1.9e-07 (1.1e-20, 3.2)	1.8e-07 (2e-27, 0.03)	0.91 (0.25, 3.1)
9.2e+03 (8.1e-08, 3e+22)	2.6 (0.024, 1.5e+02)	2.4 (0.017, 1.4e+02)	2.1 (0.019, 1.1e+02)	2.1 (0.017, 97)	1.8 (0.014, 1e+02)	1.8 (0.014, 1.3e+02)	1.7 (0.015, 89)	1.4 (0.013, 69)	1.3 (0.012, 70)	1 (0.0084, 58)	1 (0.0093, 49)	Mpred+ Pred+ MTX	0.98 (0.0092, 47)	0.95 (0.0076, 52)	0.72 (0.006, 41)	0.17 (0.0019, 1.5)	1.1e-07 (1.1e-27, 0.16)	5.6e-08 (1.3e-20, 13)	9.4e-08 (1.1e-27, 0.15)	0.93 (0.0075, 55)
4.8e+03 (2.5e-07, 2.3e+22)	2.8 (1.1, 6.8)	2.3 (0.63, 10)	2.2 (0.51, 9.9)	2 (0.52, 8.7)	1.9 (0.33, 12)	2 (0.14, 29)	1.8 (0.44, 7.7)	1.5 (0.46, 4.6)	1.4 (0.37, 5.1)	1.1 (0.31, 4.2)	1.1 (0.31, 3.7)	1 (0.021, 1.1e+02)	SSZ	0.99 (0.35, 3)	0.75 (0.21, 2.8)	0.17 (0.0058, 1.5)	2.4e-07 (3.3e-27, 0.049)	1.7e-07 (1.3e-20, 3.4)	1.9e-07 (2.6e-27, 0.039)	0.95 (0.18, 5)
4.4e+03 (2.2e-07, 2.2e+22)	2.9 (0.65, 11)	2.4 (0.73, 8.5)	2.3 (0.55, 8.7)	2.1 (0.59, 7.3)	1.9 (0.38, 11)	2.1 (0.15, 25)	1.9 (0.52, 6.7)	1.5 (0.57, 3.7)	1.4 (0.43, 4.3)	1.1 (0.35, 3.5)	1.1 (0.35, 2.9)	1.1 (0.019, 1.3e+02)	1 (0.34, 2.8)	SSZ+ MTX	0.75 (0.25, 2.5)	0.17 (0.006, 1.4)	2.5e-07 (3e-27, 0.041)	1.9e-07 (1.4e-20, 2.8)	1.9e-07 (3e-27, 0.034)	0.98 (0.2, 4.3)
6e+03 (2.7e-07, 3.2e+22)	3.8 (0.75, 18)	3.2 (1.2, 9.3)	2.9 (0.83, 9.8)	2.7 (0.91, 8.9)	2.6 (0.55, 12)	2.6 (0.23, 30)	2.5 (0.75, 6.7)	2 (0.95, 3.8)	1.9 (0.67, 4.5)	1.5 (0.73, 2.7)	1.4 (0.56, 3.3)	1.4 (0.025, 1.7e+02)	1.3 (0.35, 4.8)	1.3 (0.41, 4.1)	TCZ+ MTX	0.24 (0.0077, 1.7)	3.3e-07 (4e-27, 0.057)	2.8e-07 (1.9e-20, 4.6)	2.6e-07 (3e-27, 0.05)	1.3 (0.3, 4.6)
3.4e+04 (1.1e-06, 1.7e+23)	16 (1.5, 5.2e+02)	14 (1.8, 4e+02)	13 (1.4, 3.5e+02)	12 (1.6, 3.6e+02)	11 (1, 3.9e+02)	13 (0.65, 4.9e+02)	10 (1.4, 2.9e+02)	8.3 (1.3, 2.4e+02)	8 (1.1, 2.3e+02)	5.9 (0.84, 1.9e+02)	6.1 (0.84, 1.7e+02)	6 (0.65, 5.2e+02)	5.8 (0.66, 1.7e+02)	5.8 (0.71, 1.7e+02)	4.1 (0.59, 1.3e+02)	Lefl	2e-06 (1.7e-26, 0.38)	1e-06 (2.8e-20, 61)	1.8e-06 (1.3e-26, 0.3)	5.6 (0.59, 1.8e+02)

MPred +MTX	Pred	TOF	ABA+ MTX	Pred MTX	TOF+ MTX	Pred+ SSZ+ MTX	ETN+ MTX	MTX	CTZ+ MTX	TCZ	ADA+ MTX	Mpred +Pred+ MTX	SSZ	SSZ+ MTX	TCZ+ MTX	Lefl	IFX+ MTX	HCQ+ Pred+ SSZ+ MTX	HCQ+ SSZ+ MTX	ABA
3.4e+14 (4.6, 7.2e+28)	1.3e+07 (60, 7.1e+26)	1e+07 (51, 9.2e+26)	9.2e+06 (57, 7.7e+26)	9.3e+06 (47, 6.7e+26)	7.8e+06 (44, 6.5e+26)	1e+07 (39, 6.4e+26)	7.6e+06 (42, 5.5e+26)	6.4e+06 (35, 5e+26)	5.9e+06 (33, 5.3e+26)	4.5e+06 (24, 3.4e+26)	4.3e+06 (28, 3.9e+26)	9.1e+06 (6.4, 8.8e+26)	4.2e+06 (20, 3e+26)	4e+06 (24, 3.4e+26)	3.1e+06 (18, 2.5e+26)	5e+05 (2.6, 5.9e+25)	IFX+ MTX	7.2e+02 (5.4e-16, 1.4e+15)	0.85 (0.34, 2.1)	4.2e+06 (20, 3.3e+26)
5.9e+11 (5.1, 1.1e+28)	1.7e+07 (0.77, 2e+20)	1.4e+07 (0.62, 1.6e+20)	1.1e+07 (0.54, 1.3e+20)	1.1e+07 (0.71, 1.4e+20)	1.2e+07 (0.47, 8e+19)	2e+07 (0.37, 1.6e+20)	9.4e+06 (0.49, 1.2e+20)	7.9e+06 (0.44, 1.1e+20)	7.7e+06 (0.4, 1.1e+20)	5e+06 (0.31, 7.7e+19)	5.3e+06 (0.31, 8.8e+19)	1.8e+07 (0.074, 7.8e+19)	5.8e+06 (0.29, 8e+19)	5.2e+06 (0.36, 7.4e+19)	3.6e+06 (0.22, 5.2e+19)	9.6e+05 (0.016, 3.5e+19)	0.0014 (7.2e-16, 1.9e+15)	HCQ+ Pred+ SSZ+ MTX	0.0011 (5.3e-16, 2.1e+15)	4.9e+06 (0.25, 1.1e+20)
3.7e+14 (6.5, 7.5e+28)	1.6e+07 (72, 9.4e+26)	1.3e+07 (66, 1e+27)	1.1e+07 (66, 1e+27)	1e+07 (57, 9.4e+26)	8.6e+06 (50, 8.3e+26)	1.2e+07 (41, 9.2e+26)	9.9e+06 (52, 7.4e+26)	7.9e+06 (43, 6.4e+26)	7.4e+06 (40, 7.1e+26)	5.4e+06 (29, 4e+26)	5.6e+06 (33, 5.1e+26)	1.1e+07 (6.6, 9e+26)	5.3e+06 (26, 3.8e+26)	5.2e+06 (29, 3.3e+26)	3.8e+06 (20, 3.3e+26)	5.7e+05 (3.3, 7.6e+25)	1.2 (0.48, 3)	8.9e+02 (4.9e-16, 1.9e+15)	HCQ+ SSZ+ MTX	5.1e+06 (24, 4.2e+26)
4.2e+03 (2.4e-07, 2.1e+22)	3 (0.43, 18)	2.4 (0.65, 11)	2.3 (0.69, 7.4)	2.2 (0.55, 10)	2.1 (0.31, 12)	2.1 (0.13, 30)	1.9 (0.47, 8.6)	1.6 (0.5, 5.4)	1.5 (0.36, 6)	1.1 (0.29, 4.7)	1.1 (0.32, 4.1)	1.1 (0.018, 1.3e+02)	1.1 (0.2, 5.6)	1 (0.23, 4.9)	0.77 (0.22, 3.4)	0.18 (0.0056, 1.7)	2.4e-07 (3e-27, 0.051)0	2e-07 (9.1e-21, 4)	2e-07 (2.4e-27, 0.042)0	ABA